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Abstract
Human Hepatitis B virus (HBV) is the prototype member of the family
Hepadnaviridae that consists of enveloped, partially double stranded DNA viruses that
specifically target hepatocytes for viral replication. Although a vaccine has been available
for more than 20 years chronic HBV infection afflicts 350-400 million worldwide. It is
estimated that 0.5-1.2 million people die each year from HBV-attributable cases of chronic
hepatitis, cirrhosis, and hepatocellular carcinoma.
Significant disadvantages exist among currently available therapeutics (e.g. IFNta,
lamivudine, adefovir, etc.) that include limited efficacy and the promotion of drug-resistant
viral strains. These therapeutics are the research products of the HBV molecular biology
that can be manipulated in the laboratory setting. Future antiviral drug therapy is
dependent upon the development of better cell culture systems that will allow the study of
the complete viral life cycle.
The use of primary human and primate hepatocytes is restricted by multiple
experimental limitations including a rapid loss of susceptibility to infection in culture, lot-
to-lot variability inherent in primary cell culture, and the necessity of treatment with
chemical agents such as DMSO for reproducible infection. Permissive cell lines are
capable of supporting viral replication upon transfection with the HBV genome. These
cell lines have helped to elucidate the later events in the viral life cycle. However, there is
less understanding of the early stages that include virus attachment, internalization,
uncoating, nuclear transport, and genome repair.
Our group has developed an in vitro system that recreates many of the features of a
perfused capillary bed structure. Various metrics (e.g. biochemical production, tissue
morphology, liver-enriched mRNA expression, and drug metabolism) confirm that this
system maintains a well-differentiated liver phenotype. Using DHBV as a surrogate
model, this study has attempted to demonstrate that hepatocytes maintained in a more
sophisticated culture system retain susceptibility to infection. This study has endeavored
to establish the perfused three-dimensional culture system as potential tool to study early
events of the viral life cycle. This research lays the foundation for the future development
of a human HBV infection model in which early stages of the viral life cycle can be
studied and therapeutic targets identified.
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Chapter 1
Introduction, Background and Motivation
1.1 Global Impact
Human Hepatitis B Virus (HBV) is the prototype member of the family
Hepadnaviridae that consists of enveloped, partially double-stranded DNA viruses that
specifically target cells in the liver for viral replication. Although a vaccine has been
available for more than 20 years chronic hepatitis B afflicts -5% of the world's population
(350 - 400 million) [11 ]. It is estimated that 500,000 to 1.2 million people die each year
from HBV-attributable cases of chronic hepatitis, cirrhosis, and hepatocellular carcinoma
[12, 13].
In terms of geographic distribution of the chronic HBV infection more than 75% of
the world's carriers are located in the Western Pacific and Southeast Asia region which
include over 40 countries (Fig. 1-1) [14, 15]. In the U.S. there are -1.25 million
Figure 1-1. Worldwide geographic distribution of chronic hepatitis B virus infection as
of 2005. HBsAg is a viral antigen used as a serologic marker to indicate active HBV
infection. HBsAg prevalence may vary within countries by subpopulation and locality.
Figure taken from [8].
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chronically infected individuals and -one-third will develop clinical complications due to
chronic HBV infection [13]. In an effort to assess the economic burden one study
estimated that over a 2-year period chronically infected HBV patients spent -$40,512 for
healthcare services and drugs [16]. Considering the high morbidity and mortality of HBV-
related diseases the accumulated costs are substantial. In countries where HBV is endemic
the costs are even more significant. A South Korean study estimated that in 1997 $623.3
million (USD) were spent on HBV disease-related medical costs (-3% of the South
Korean national healthcare expenditure for 1997) [17].
1.2 Current anti-HBV Therapeutics
Interferon alpha (IFNa) is the only agent known to induce long-term remission,
characterized by the reduction of viral DNA and hepatitis B e antigen (HBeAg) to
undetectable levels in the patient's serum, in -one-third of patients treated over a course of
4-6 months [18-20]. This naturally occurring cytokine has a dual mode of action; first it
inhibits viral replication; and second it enhances the immunological response of the host
against the virus. The disadvantages associated with IFNc include a limited efficacy rate,
undesirable side effects, and an inconvenient dosing regimen (3 injections per week).
Studies have shown that the addition of a polyethylene glycol (PEG) molecule to IFNa
significantly increases the half-life and leads to more sustained activity[21, 22]. This
prolonged half-life results in the need for only one injection per week. Among the two
pegylated IFNs (peginterferon a-2a, peginterferon a-2b) that have been studied,
peginterferon a-2a has been approved for chronic hepatitis B treatment in the US.
In addition nucleoside analogues such as lamivudine have been approved for
treatment of chronic HBV infection. Nucleoside analogues are synthetic molecules that,
following conversion into nucleoside triphosphate equivalents, compete with natural
nucleoside triphosphates for incorporation into viral DNA by the viral DNA polymerase.
Since these analogues lack a bond site necessary to link it to an adjacent nucleoside their
incorporation effectively terminates the elongation of nascent viral DNA chains and
therefore inhibits viral replication. Lamivudine which is administered orally has minimal
side effects. However, it does display a modest efficacy rate of 20-30% following a 12
month dosing regimen [23]. Following therapy termination most patients experience a
relapse evidenced by the detection of viral DNA and HBeAg in the serum [24].
Continuous lamivudine treatment is necessary for a sustained therapeutic effect. This is a
major drawback when combined with the observation that lamivudine-resistant HBV
species emerge during long-term treatment [23, 24]. These species have mutations in the
YMDD amino acid motif in the HBV DNA polymerase gene. Within 30 months YMDD
mutants can make up to 70% of the HBV population [23]. This emergence of YMDD
mutants is also associated with relapses [23].
Clinical trials with adefovir dipivoxil, another nucleoside analogue, demonstrated a
significant reduction in viral markers in the serum of patients who had developed
lamivudine-resistant HBV strains[25, 26]. Entecavir, the latest nucleoside analogue to be
approved in the US, has also shown to be efficacious in patients demonstrating lamivudine
resistance [27]. The optimal treatment duration, long-term safety, and durability of the
response is still being investigated.
Today, combination therapies of the drugs mentioned above are being evaluated as
potential treatment strategies [28-30]. However, due to the persistence of HBV in infected
patients long-term antiviral therapy is normally required. As mentioned above a patient
undergoing this long-term therapy risks selecting drug-resistant mutant HBV strains and
developing progressive liver disease. In-depth analysis of such mutant strains, including
their infectivity and replication fitness, has been hampered by the lack of user-friendly cell
culture systems and animal models which will be discussed in detail later in the chapter.
Understanding the process of selection of drug-resistant mutants is critical to developing a
combination therapy that will prevent such drug resistance.
Neither IFNa nor the various nucleoside analogues available represent the final
solution for treatment of chronic HBV infection. IFNa has limited efficacy and
considerable side effects while nucleoside analogues must be continuously taken and lead
to the development of drug resistant mutants. Current therapeutics are the result of
research based on the present understanding of certain aspects of the viral life cycle which
are manipulable in the laboratory setting. Future antiviral drug therapy is dependent on the
development of better cell culture systems. To date, no successful in vitro system has been
developed for chronic HBV infection wherein the entire viral life cycle can be studied.
More is known about the later events in the viral life cycle (i.e. transcription, encapsidation
reverse transcription, virion assembly, export) due to studies in which the viral genome is
transfected into established hepatoma cell lines (e.g. HepG2, Huh7). However, there is
less understanding of the early stages that include virus attachment, internalization,
uncoating, genome repair, and nuclear transport. These cell lines do not mimic natural
infection which limits their usefulness. An in vitro system that will allow researchers to
target other aspects of the viral life cycle is needed.
Such an in vitro system would incorporate the understanding that the liver's
function is connected to the liver's structure. Standard cell culture systems do not
successfully mimic liver structure and fail to maintain liver function. This thesis will detail
the development of a user-friendly in vitro system in which the entire HBV life cycle can
be studied. A brief review of liver organization will better inform the later discussion of
the liver's role in HBV infection. In the rest of this chapter the unique architecture of the
human liver, the host organ for HBV will be reviewed. The genomic organization and the
protein components of the virus will be summarized. Currently available in vitro models
will be surveyed, focusing specifically on Duck HBV (DHBV) which was used exclusively
in this thesis research. Finally, the cellular determinants of both the host restriction and
tissue restriction of DHBV will be reviewed.
In the subsequent chapters the key features of the three-dimensional microscale
bioreactor will be reported. This will be followed by a detailed description of the methods
used to cross the species barrier and study DHBV in rat liver cells. Next, efforts to
demonstrate that cells maintained in our system remain susceptible to DHBV infection
after significant time periods in culture will be described. Finally, the thesis will conclude
with a discussion of the significance and future implications of this research.
1.3 General Anatomy
The mammalian liver is an organ whose complex architecture is a reflection of the
thousands of vital functions it is required to perform. Macroscopic anatomy divides the
human liver into two major (right, left) and two minor (caudate, quadrate) lobes. The liver
is supplied with blood from both the portal vein and the hepatic artery. Approximately
80% of the blood entering the liver originates from abdominal tissues (i.e. stomach,
intestines, spleen, pancreas). This poorly oxygenated blood travels through the portal vein
while the remaining blood is supplied by the hepatic artery. On a microscopic scale these
blood vessels branch off and penetrate through out the liver tissue. Terminal branches of
these vessels feed the hepatic sinusoids, fenestrated capillaries which facilitate
transvascular exchange between the blood and the functional cells discussed later in this
chapter. The blood drains into central veins that eventually merge and empty into the
inferior vena cava, a large vein which enters the heart via the right atrium.
Various organizational concepts have been proposed in order to understand both
the structural and functional units of the liver. In 1833 Kiernan described the classic
hepatic lobule as the structural unit of the liver, the smallest non-repeating structure [31].
Polyhedral in shape, the hepatic lobule consists of a central vein (also known as a terminal
hepatic venule) at the center and a portal triad at each comer of the polygonal structure.
Each portal triad consists of the portal vein, hepatic artery, and the bile duct (Fig 1-2). As
an exocrine gland (which will be discussed later) specific cells within the liver produce
bile, a solution composed of detergent-like molecules. The bile is secreted into bile
canaliculi, fine canal-like structures. Spread throughout the tissue these structures
continually merge to form increasingly larger ducts, culminating in the common bile duct.
A portion of this ductwork runs parallel to a branch of the portal vein and the hepatic artery
to form a structure known as the portal triad. Single-cell thick layers of hepatocytes form
cord-like structures extending from the portal triads to the central venule. Blood entering
this unit would travel from the periphery (hepatic artery, portal vein) to the axis where it
would drain out through the central vein. In most mammals, the periphery of the hepatic
lobule is poorly defined such that the sinusoids from neighboring lobules are connected.
Therefore, portal triads are supplying blood to more than one central vein. It was also
noted that within the same lobule there are differences in oxygenation, metabolic functions,
and response to certain diseases depending on the region.
He
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Figure 1-2. Classic hepatic lobules are represented by hexagons (solid lines); Rappaport's
acinus is represented by rhombus (dotted line). Figure taken from:
http://www.mercksource.com/pp/us/cns/cnshealthlibrary.jspzQzpgzEzzSzppdocszSzuszS
zcnszSzcns_health_library_mainzPzhtm
In 1954 this led Rappaport et al. to propose a functional unit of the liver known the
acinus [32]. By injecting ink or colored gelatin into the portal vein of various mammals
(e.g. rabbit, dogs, humans) they delineated a roughly diamond-shaped area whose four
corners consist of two opposing portal triads and two opposing central veins (Fig. 1-2).
The axis is formed by a portal tract containing a terminal hepatic venule and hepatic
arteriole which branch within the tissue forming sinusoids that eventually drain into the
central veins on both ends of the acinus. The acinus is further subdivided into three zones.
The zonation reflects the order in which these areas receive blood supply and therefore also
reflects different levels of oxygenation. Cells located immediately adjacent to the portal
tract (zone 1) receive blood rich in oxygen and nutrients. Zone 2 represents an
intermediate area and zone 3 includes the periphery of the acinus. The greater distance
from the incoming blood at the portal tract results in access to less oxygen and nutrients in
zones 2 and 3. Hepatocytes located in the different zones have been shown to have
different morphology, gene expression, and metabolic activity[33-36].
Figure 1-3. Zonation of Rappaport's acinus. Figure taken from [1].
Over the past 30 years several alternative functional units of the liver have been
proposed (Table 1-1) because three dimensional studies of lobular angioarchitectures [37,
38] and enzyme distributions [39] have highlighted contradictions to the concept of the
acinus.
Taking this additional information into account the functional unit was modified so
that now it was actually a subunit of Kiernan's classic hepatic lobule described earlier. In
Evolution of the functional unit of the liver.
Year Unit Proposed By
1665 Lobular architecture Weppler
1833 Classic hexagonal lobule Kiernan
1906 Portal lobule Mall
1954 Liver acinus Rappaport
1979 Primary lobule Matsumoto
1988 Single sinusoid Bloch and McCuskey
1989 Metabolic Lamers et al.
1989 Zonal circulation Quistorff and Romert
1993 Choleon Hofman
1997 Microcirculatory subunit Ekataksin and Wake
and choleohepaton
Table 1-1. Different proposals for the functional unit of the liver. Adapted from [2].
1979 using three-dimensional angioarchitectural reconstructions of human liver
Matsumoto and Kawakami divided each classic lobule into 6-8 cone-shaped primary
lobules. The convex surface of the primary lobule is located at the periphery of the classic
lobule while the vertex of the primary lobule is located at the central venule (the center of
the classic lobule). Other functional units such as the single sinusoid and the choleon are
reviewed in MacSween et al. [40]. While the liver has no clear-cut anatomical units,
efforts to define such units are useful in understanding the function of the organ in both
normal and pathologic states.
1.4 Liver Microenvironments: Sinusoid & Intrahepatic Bile Duct System
To help illustrate the close relationship between the unique structure and function
the main purpose and phenotypic characteristics of each major cell type will be described
in this section. The composition and cellular arrangement within the sinusoidal
microenvironment is included in Fig 1-4.
A
B
Hepatocytes Non-Hepatocytes
(parenchymal cells) nonparenchymal cells)
-65% -35%
Sinusoidal Kupffer Cells Lymphocytes Biliary Cells Stellate Cells
Endothelial Cells (Pit cells, T cells, B cells)
-50% -20% -20%/ -5% -5%
Figure 1-4. A) Diagram of sinusoidal microenvironment. B) The percentage of each cell
type present in the liver in relation to total number of cells. Image in (A) is taken from [4].
1.4.1 Hepatocytes
Approximately 65% of the cells in the adult mammalian liver are hepatocytes [41].
These polygonally-shaped cells are arranged in single-cell thick plates which extend from
the portal triads to the central vein of the classic hepatic lobule. With regard to surface
polarity these cells possess extensive, microvillus-rich basolateral surfaces that take up
nutrients and oxygen from passing blood while the canalicular surface, which is -10% of
the hepatocyte surface, is used to secrete bile which aids in the process of digestion.
Hepatocyte functions fall into five main categories: 1) carbohydrate metabolism 2) fat
metabolism 3) protein metabolism 4) detoxification and 5) storage. One example from the
first category is the supplying energy to the organism by the maintenance of normal blood
glucose levels. Hepatocytes are able to take up glucose present in the blood following a
meal, store it as glycogen, and later release it when blood concentrations begin to decline.
Hepatocytes are also capable of gluconeogenesis, synthesis of new glucose. An example
of fat metabolism includes the ability to synthesize cholesterol and phospholipids which is
packaged and secreted with lipoproteins which transfer cholesterol between the liver and
body tissues. Another important example is the production of bile, a complex aqueous
fluid containing water, electrolytes and a battery of organic molecules including bile acids,
cholesterol, phospholipids and bilirubin, which all aids in fat digestion as well as
elimination of toxic lipophilic compounds. With regard to protein synthesis many blood
proteins including clotting factors and albumin are synthesized and secreted by
hepatocytes. These cells also remove harmful substances from the blood and break them
down or transform them into less harmful compounds. Ammonia, for example, is
transformed into urea and excreted into the urine. In terms of storage hepatocytes store fat-
soluble vitamins, folate, and minerals such as copper and iron.
1.4.2 Liver Sinusoidal Endothelial Cells
Based on the brief description of some of the major functions accomplished by
hepatocytes it is straightforward to appreciate why about 30% of the total blood passes
through the liver every minute [4]. To maximize the access each hepatocyte has to the
blood the liver employs a unique microarchitecture. The blood delivered to the liver
travels through capillaries known as sinusoids (Fig 1-5). Capillary walls are formed by
endothelial cells which comprise -50% of the non-hepatocyte population in the liver [4].
These endothelial cells have attenuated cytoplasms punctuated with 150 - 175 nm
diameter pores known as fenestrae. These fenestrae occur at a frequency of 9 - 13 per [tm 2
and occupy 6 - 8% of the endothelial surface using scanning electron microscopy (SEM)
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Figure 1-5. A) Diagram of sinusoid B) Scanning electron micrograph (SEM) of sinusoida
microenvironment. Fenestrae are -100nm in diameter and sinusoid width is -5[tm. Imag
taken from www.tracy.kl 2.ca.us/thsadvbio/images/sinusoid.gif and image B taken from
http://en.wikipedia.org/wiki/Liver_sinusoid
[42]. Single-cell thick plates of hepatocytes (i.e. parenchyma) are located adjacent to the
sinusoidal wall, separated only by a perisinusoidal space referred to as the space of Disse.
There is very little basal lamina associated with the sinusoidal endothelium. Along with
the fenestrae it makes the sinusoidal wall a rather permeable structure. Fenestrae are
grouped into clusters and act as sieve plates allowing solutes and particles to pass back and
forth between the sinusoidal lumen and the space of Disse, thereby gaining access to
neighboring parenchymal cells and vice versa. Studies have shown that endothelial cell
fenestrae are dynamic structures whose diameter and number can vary in response to
factors such as hormones, drugs, hypoxia, virus infection, cirrhosis, fibrosis, and
hepatocellular carcinoma [43-50]. In addition to these fenestrae endothelial cells also
deliver various macromolecules to the parenchyma via transcytosis. As in Rappaport's
SA
acinus where cells in different zones displayed both morphological and functional
heterogeneity sinusoids also demonstrate regional variations. Sinusoids in zone 1 are
narrower and more circuitous but become broader and straighter in zones 2 and 3 [51].
1.4.3 Kupffer Cells (KCs)
Within the sinusoidal lumen Kupffer cells, resident macrophages, are amoebid-
shaped cells attached to the surface of the endothelium. KCs constitute -20% of the non-
hepatocyte cells in the liver and 80-90% of the tissue macrophages in the body [52].
Viewed as a "front line of defense", KCs are strategically positioned to encounter foreign
particles, tumor cells bacteria, yeast, viruses and parasites in the passing blood. Upon
activation by antigen or inflammatory stimuli their major role is the clearance of such
material via phagocytosis. KCs are also capable of passing through the space of Disse in
order to phagocytose apoptotic hepatocytes. While they are spread throughout the liver
there are differences in the population density, cytologic characteristics, and physiologic
functions within the different zones of the liver acinus. Larger KCs tend to be located in
the periportal region of the acinus where they will encounter incoming pathogen-laden
blood [53]. Periportal KCs have been reported to have higher lysosomal enzyme activities
and greater phagocytic capacity than the smaller KCs from the midzonal and perivenous
regions of the acinus [53]. KCs appear to be derived from bone marrow-derived
monocytes circulating in the blood which migrate into various tissues and transform into
macrophages [54].
1.4.4 Hepatic Stellate Cells (HSCs)
HSCs, which are also referred to as Ito cells or Fat-storing cells, reside in the space
of Disse and account for -5% of the total cells in the adult liver [55, 56]. In normal liver
they are the principal storage site for vitamin A metabolites within lipid droplets located in
the cytoplasm. This storage accounts for 40-70% of the vitamin A within the body [55].
HSCs demonstrate atleast two different phenotypic states. In the quiescent state HSCs
display a dendritic phenotype in which long cytoplasmic extensions that contact both the
neighboring hepatocytes and the adjacent LSECs. These extensions, which vary in range
from 60-140 [tm, modulate sinusoidal blood flow via contraction and relaxation [57, 58].
Other quiescent activities include synthesizing and releasing extracellular matrix (ECM)
components and metalloproteinases, and erythropoietin synthesis. HSC activation
following liver injury results in the transformation to the second phenotype and results in
changes in the gene expression profile, change from a dendritic-like to a fibroblast-like
shape, and a loss of vitamin A-containing lipid droplets [59, 60]. HSC activation is
triggered by multiple cytokines and stimuli provided by various cells including
hepatocytes, KCs, LSECs, and infiltrating inflammatory cells [57]. Activated HSCs
orchestrate the wound healing response.
As with other cell types within the liver, HSCs demonstrate intralobular
heterogeneity with smaller, simpler HSCs present at the periphery of the lobule and larger
HSCs with more numerous cytoplasmic extensions toward the center of the classic lobule
[58]. Vitamin A storage also appears to demonstrate a zone-depended distribution [58].
Following the resolution of the liver injury it has not been conclusively determined
whether activated HSCs revert to the quiescent phenotype or are cleared by apoptosis.
However, increasing evidence points to the role of apoptosis in the elimination of activated
HSCs [61, 62].
1.4.5 Pit Cells
Pit cells are located inside the sinusoidal lumen where they adhere to both the KCs
and the LSECs. Morphologically, these cells are defined as large granular lymphocytes
(LGLs) that are characterized by spherical dense granules and rod-cored vesicles [63, 64].
Functionally, they are defined as natural killer cells that kill target cells by several
mechanisms that include the release of cytoplasmic granules containing perforin and
granzyme that lyse cells via osmotic rupture, induction of death receptor-mediated
apoptosis, and augmentation of other immune cells through interferon-gamma production
[63]. Pit cells display a high level of natural cytotoxicity against a variety of tumor cell
lines indicating their role in the prevention of metastasis and the suppression of tumor
initiation within the liver [63, 65].
1.4.6 Cholangiocytes
After bile is initially secreted into the bile canaliculus (formed by two adjacent
hepatocytes) it travels through ductules formed by cholangiocytes. These biliary epithelial
cells are organized into a three-dimensional network of interconnecting ducts of varying
size (Table). These cells account for 3-5% of the total liver cell population [66]. In the
smaller ductules the cholangiocytes are roughly cubic but as the ductules become larger the
cholangiocytes are more columnar in shape. Other morphological differences include the
observation that small cholangiocytes have a larger nucleus to cytoplasm ratio which
suggests that they are more undifferentiated cells in comparison to large cholangiocytes
[67]. Cholangiocytes also display functional heterogeneity. As the bile travels through the
duct network it is modified by a series of regulated reabsorptive and secretory events
before eventually reaching the small intestine. Small and large cholangiocytes express
different enzymes and membrane transporters [68, 69]. The large cholangiocytes which
form the larger ductules have been shown to respond to certain hormones while the small
cholangiocytes do not respond which suggests that the small cholangiocytes may form
more passive duct structures that deliver the bile from the bile canaliculus to the large
hormone-responsive ducts where it is actually modified [70]. However, small
cholangiocytes have been shown to compensate for the loss of large cholangiocyte function
in certain injury models [67]. The biliary epithelium also demonstrate specific
compartments that differentially respond to injury, hepatic toxins, or dietary regimes
although the mechanisms by which this occurs are undefined [71-73].
1.5 Interactions within the Sinusoidal Microenvironment
In standard in vitro systems it has been observed that hepatocytes progressively
lose a number of liver-specific functions. This dedifferentiation is a result of changes in
gene expression and diminished transcription of relevant liver-specific genes. Underlying
factors include the ischemia-perfusion stress induced during the isolation process, the
disruption of the normal tissue architecture, and the adaptation to the in vitro environment.
An in vitro environment that restored fundamental aspects of normal tissue architecture
would go a long way in maintaining the liver phenotype.
Normal tissue architecture maintains the various liver phenotypes via cell-matrix
interactions, paracrine signaling, and cell-cell interactions within the sinusoidal
microenvironment. The loss of such interactions leads to the loss of cellular phenotype
and function. Therefore, as highlighted in this section it is important for an in vitro culture
system to replicate the critical sinusoidal environmental cues in order to maintain proper
cellular function.
1.5.1 Cell-Matrix Interactions
The sinusoidal surface of hepatocytes are in contact with various extracellular
matrix (ECM) components that include type IV collagen, laminin, fibronectin, and heparin
sulfate proteoglycans that are located in the space of Disse. When absent from the
microenvironment hepatocytes will produce ECM constituents in a negative feedback
fashion [74]. Hepatocytes isolated from the liver and cultured on ECM-derived gels have
been shown to maintain a differentiated phenotype, expressing liver-specific mRNAs such
as serum albumin [75, 76]. Freshly isolated rat heps isolated on Matrigel, a solubilized
basement membrane preparation, regained mRNA expression for several constitutive
cytochrome P450 (CYP450) proteins, metabolism enzymes used to detoxify and eliminate
foreign chemicals introduced into the body [77]. Phenotypic changes occur in various
liver cells when there are changes in the microenvironment. For example, during
fibrogenesis wherein normal low-density basement membrane in the space of Disse is
converted to high-density interstitial type matrix LSECs deposit ECM components and
cytokine-activating factors and stellate cells become activated [55]. These results
demonstrate the importance of cell-matrix interactions for homeostasis and therefore, the
importance to mimic such interactions in an in vitro liver analog.
1.5.2 Soluble Ligands
The coordination of various liver functions requires intercellular communication
that is mediated by various molecules including hormones [78, 79], eicosanoids [80-82],
reactive oxygen species [52, 83], and cytokines [80, 84]. Liver regeneration following
injury (e.g. partial hepatectomy) utilizes multiple interconnected networks of cytokines,
growth factors, and metabolic pathways to restore the original organ mass [85]. It has been
shown that NPCs synthesize various cytokines and growth factors while hepatocytes
express a variety of receptors for these molecules. Therefore, it is crucial that any in vitro
system that aims to reconstruct the sinusoidal microenvironment will need to incorporate
these soluble ligands. Adding such ligands directly to the cell culture media is not always
ideal since the precise role and concentration of individual ligands are not completely
understood. Other approaches have investigated co-culturing hepatocytes with non-
parenchymal cells in physiological ratios [86].
1.5.3 Cell-Cell Interactions
Three main types of cellular junctions include anchoring junctions (adherens
junctions & desmosomes), occluding junctions (tight junctions), and communicating
junctions (gap junctions). Homotypic interactions within non-parenchymal cell
populations vary such that Pit cells display no physical interaction, Kupffer cells
demonstrate no physical interaction, LSECs have poorly-defined cellular contacts with
each other at their periphery, and stellate cells are interconnected via anchoring junctions
and communicating junctions [87]. Hepatocytes demonstrate an abundance of cell
junctions which emphasize the need for mutual cooperation in the execution of liver-
specific function. Hepatocyte-specific functions that have been shown to require the
presence of either adherens junctions or gap junctions include albumin secretion [88, 89],
ammonia detoxification [90], glycogenolysis [91], bile secretion [92-95], and xenobiotic
biotransformation [96-98]. In order to isolate hepatocytes for in vitro culture the liver is
normally subject to the two-step collagenase perfusion technique which chemically and
mechanically disrupts normal cell junctions. Efforts to reestablish these junctions in vitro
include continuously rotating hepatocytes in suspension or using cell-repelling substrata in
order to form multicellular aggregrates known as spheroids. Co-culturing has also been
explored [99]. These cell-cell contacts are prerequisites to successfully imitate the natural
sinusoidal microenvironment and therefore retain liver-specific function.
1.6 Hepatitis B Virus
1.6.1 Genome Organization
The genome located in infectious human HBV particles is a 3.2kb relaxed, circular,
partially double-stranded species (Fig. 1-6). Cohesive 5' ends maintain the circularity of
this species. This asymmetric genome includes a minus strand that is unit length and has a
protein covalently bound to its 5' end and a plus strand that is less than unit length and has
a capped oligoribonucleotide at it's 5' end. Although the plus strand has a fixed 5' end the
Figure 1-6. HBV genome organization. Relaxed, circular, 3.2kb, partially double-
stranded species includes four overlapping open reading frames. Taken from [3].
3' end is variable such that the genome contains a single-stranded region of variable
length. The genome is highly compact such that every nucleotide is located within a
coding region and more than half the nucleotides are translated in more than one open
reading frame (ORF). The genome contains 4 overlapping ORFs: the P ORF that encodes
the viral polymerase/reverse transcriptase, the C ORF that encodes the core protein that
forms the nucleocapsid, the S/preS ORF that encodes the envelope glycoproteins, and the
X ORF that encodes the X protein whose precise function is not completey elucidated.
The main functions of these proteins will be briefly reviewed in the following sections.
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Figure 1-7. A) Scanning election micrograph of different HBV particles present during
natural infection. Taken from http://biology.kenvon.edu/slonc/bio38/scuderi/hbv3b.gif.
B) Diagram of Dane particle (infectious particle). Taken from
http://www.rit.edu/-japfaa/HBV.jpg
1.6.2 Envelope Proteins
Cells Infected with HBV produce three types of virus-related particles that include
42nm double-shelled infectious particles referred to as Dane particles, 20nm spheres, and
20nm diameter filaments of variable length (Fig. 1-7 ). The envelope of all three particles
contain three surface glycoproteins and host-derived lipoprotein. The three glycoproteins
are all expressed from a single open reading frame. The domain present in all three
glycoproteins is referred to as the S domain. The small envelope protein (S) consists of
only this 226 amino acid (aa) domain. The two larger envelope proteins contain additional
N-terminal domains created by initiation at upstream start codons. The middle envelope
protein (M) contains an extra 55 aa domain referred to as preS2. The large envelope
protein (L) contains preS2 and a unique 108 or 119aa domain referred to as preS 1. Dane
particles contain S,M, and L proteins with M and L present in roughly equal amounts
constituting -30% of the envelope protein content [100]. Sphere particles contain mainly
S and M proteins while filaments contain a greater amount of L protein [101]. All three
envelope proteins are glycosylated and display a complex transmembrane topology.
Interstingly, the L protein demonstrates two different conformations. In the i-preS
conformation both preS domains are located in the cytosol while in the e-pres
conformation the preS domain are located within the ER lumen of the host cell. Studies
have shown that the i-preS conformation is essential for nucleocapsid envelopment [102,
103]. Following translation -50% of the L proteins switch from the i-preS conformation
to the e-preS conformation [104, 105]. In the e-preS conformation the preS domains are
exposed on the virion surface and participate in virus receptor binding which will be
discussed further in Section 1.7.1.1. The mechanism behind the change in conformation is
not well understood but is thought to involve molecular chaperones that include cytosolic
Hsc70 and Hsp40 [106]. Studies have also shown that the L protein is myristylated which
is not required for virion assembly but is required for infectivity [107-109].
1.6.3 Core Protein
The icosahedral viral capsid is formed by multiple copies of a single protein (C
protein; 183 or 185 aa depending on genotype). Assembly requires the initial formation of
dimers of core protein stabilized by two disulfide bonds. The final capsid, held together by
weak interdimer interactions, appears as two different types that are both found in infected
human liver [103]. One type has 90 dimers with a diameter of 30nm and icosahedral T = 3
symmetry. The other type has 120 dimers with a 34nm diameter and icosahedral T = 4
symmetry. The capsid shell is fenestrated with pores ranging from 12-15 A diameter
which allows the free diffusion of nucleotides into and out of the nucleocapsid lumen. An
arginine-rich domain located in the C-terminus has been shown to be required for viral
nucleic acid packaging implying that this domain is present in the lumen of the fully-
assembled nucleocapsid [110]. However, it has been demonstrated that trypsin can remove
this domain from -50% of the C protein chains in recombinant HBV capsids [103]. This
suggests the possibility that while some of the arginine-rich domains are located in the
lumen another portion of these domains are present on the outer surface of the
nucleocapsid.
1.6.4 Viral Polymerase
The HBV Polymerase (P) is a multifunctional protein that consists of four
domains that include the amino terminal protein (TP), the spacer, the polymerase/reverse
transcriptase (RT), and the C-terminal RNaseH domain. The RT catalyzes RNA and
DNA-dependent DNA polymerization, the RNase H functions to degrade RNA from the
RNA-DNA duplexes generated during viral DNA synthesis, the TP is a protein primer
necessary to initiate reverse transcription, and the spacer is a highly variable, nonessential
tether between the TP and the RT domains [3, 111 ]. The rate of virion production is
estimated to be on the order of 1011 virions per day while due to the lack of
proofreading/editing ability the error rate of the HBV P has been calculated as 10-7 per
nucleotide per day [112, 113]. Due to these factors viral populations within the host are a
heterogeneous mix known as quasi-species. As mentioned earlier (Section 1.2), mutations
in the YMDD motif located in the P gene leads to lamivudine-resistant virions.
1.6.5 HBx protein
This protein was originally termed X because its unknown function and lack of
homology with known proteins. The HBx protein has a molecular mass of 17.5kDa. Little
else is known about the protein structure because there is no crystal model currently
available. While the precise function is unresolved the HBx protein is regarded as a
multifunctional viral regulator that has been shown to transactivate the transcription of a
wide range of viral and cellular genes, to stimulate various cytoplasmic signal transduction
pathways, and to induce liver cancer in transgenic mice. Some studies have shown that
HBV replication is observed both with wildtype HBV and X-defective mutants in both
Huh7 and primary rat hepatocyte in vitro culture, suggesting that HBx is not essential for
the viral life cycle [114-116].
1.7 Animal Models
Besides humans, chimpanzees are the only animal that is fully permissive to infection
by human HBV [117]. Research using chimpanzees has been crucial in safe vaccine
development, evaluation of therapeutic agent efficacy, and elucidation of the immune
response [117]. There is accumulating evidence of hominoid primates (e.g. gibbons,
orangutans, and rhesus monkeys) being susceptible to human HBV but due to the large
size, cost, and ethical constraints their use is limited [11]. Based on their phylogenetic
closesness to primates and their adaptability to the laboratory environment, tree shrews
have been tested for their susceptibility to HBV. Inoculation with HBV-positive human
serum resulted in evidence of infection (e.g. viral DNA replication in the liver, HBsAg
secretion into serum, production of antibodies to HBsAg and HBcAg) [118, 119]. While
this infected proved to be inefficient the full potential of this model is still being
investigated.
The use of primary human and primate hepatocytes is restricted by multiple
experimental limitations including a rapid loss of susceptibility to infection in culture, lot-
to-lot variability in susceptibility to infection, and the necessity of treatment with chemical
agents such as DMSO for reproducible infection [107, 108, 120]. Permissive cell lines
(e.g. HepG2, Huh7) are capable of supporting viral replication upon transfection with the
viral genome. HepG2.2.15, a subline of HepG2, is stably transfected with multiple copies
of the HBV genome [121]. HepG2.2.15 cells express all viral RNAs and proteins, produce
viral genomes, and secrete virus-like particles. These cell lines have shed greater light on
the later events in the viral life cycle (i.e. transcription, encapsidation reverse transcription,
virion assembly, export). However, there is less understanding of the early stages that
include virus attachment, internalization, uncoating, genome repair, and nuclear transport.
These cell lines do not mimic natural infection which limits their usefulness. An in vitro
system that will allow researchers to target other aspects of the viral life cycle is needed.
Recently, a cell line known as HepaRG was shown to be susceptible to infection
under certain conditions. In the presence of PEG, DMSO, and/or hydrocortisone HepaRG
cells exhibit hepatocyte-like morphology, express liver-specific functions (e.g. albumin,
aldolase B, CYP3A4), and demonstrate phase I and phase II drug metabolism enzyme
activity in the range of normal human hepatocytes [122]. DMSO and hydrocortisone are
known inducers of cell differentiation although the underlying mechanism is not known.
Since human HBV demonstrates such a narrow host range with limitations in the
previously described models other hepadnaviruses in their natural hosts were investigated.
With regard to other non-primate hepadnaviruses none have been found in commonly used
laboratory animals such as mice and rats. Research led to the discovery of a hepatitis B
virus in the North American woodchuck. Woodchuck hepatitis B virus (WHV) is -60%
similar to human HBV, it causes chronic hepatitis and hepatocellular carcinoma [123].
This model is useful in studying the fundamental pathogenetic and therapeutic aspects of
hepadnaviral infection. Disadvantages of this model include difficulty in handling the
animals, difficulty in breeding these animals in captivity, outbred animals that are
frequently used are usually infested with other pathogens, and that no experiments can be
performed while these animals hibernate. Another disadvantage is the current lack of cell
lines that efficiently support replication of cloned WHV DNA. A review of this model is
available elsewhere [124].
Hepadnaviruses are subdivided into two categories based on sequence homology;
orthohepadnaviruses which infect mammals and avihepadnaviruses which infect birds.
Duck HBV (DHBV) was the first avihepadnavirus detected while others have been
isolated more recently from grey herons, snow geese, white storks, and cranes.
Avihepadnaviruses share little sequence homology with orthohepadnaviruses (-40%).
DHBV expresses two major envelope proteins (instead of three) (Section 1.6.2). Similar
genome organization, virus structure, and replication characteristics among hepadnaviruses
warrant the study of hepadnaviruses found in other species. Many of the principles of
hepadnavirus life cycle were elucidated by studying duck hepatitis B virus (DHBV) as a
model for HBV. Elcuidated principles include the replication by reverse transcriptase
[125], cccDNA formation [126], and host-range determinants [127-129]. However,
reproducible in vitro infection of primary duck hepatocytes requires culture conditions that
incorporate 1.5-2% DMSO whose mechanism of action is unknown [130, 131]. Even with
such artificial additives the kinetics of in vitro infection are slow and inefficient when
compared to in vivo infection of neonatal ducklings [132].
1.7.1 Host Specificity
Viral infection begins with the attachment of the viral particle to its
receptor/complex on the surface of the host cell. Following receptor binding the enveloped
virus is taken into the cell via receptor-mediated endocytosis. Escape from the late
endosomal compartment results in the release of the viral nucleocapsid into the cytoplasm.
The nucleocapsid is transported to the host cell nucleus whereupon the viral DNA is
released into the nucleus. Once inside the nucleus host cell machinery convert the viral
DNA into cccDNA which will serve as a master template for all subsequent viral
transcripts. As mentioned earlier one of the defining characteristics of all hepadnaviruses
is a narrow host range such that only the natural host and those closely related species are
susceptible to infection. However, this restriction is not observed when viral genomes are
artificially delivered to the nuclei of cell lines derived from a normally non-susceptible
species. One interpretation is that it is an early life cycle event (i.e. attachment, entry,
fusion) determines the host range for the hepadnavirus and the cellular factors that
facilitate later events (i.e. viral genome replication and viral assembly) are not host range
determinants. Support for this interpretation comes from a study in which DHBV particles
were able to bind to Pekin duck hepatocytes (natural host) but were unable to bind to cells
that are not susceptible to DHBV infection including Pekin duck fibroblasts, chicken
hepatocytes, and Muscovy duck hepatocytes [133]. The difference in susceptibility
corresponded to a difference in the ability to bind the DHBV particles which points to an
early life cycle event such as virus attachment to a cell surface receptor being the host
range determinant.
1.7.1.1 Duck Carboxypeptidase D (DCPD)
To identify possible hepatocyte surface molecules that facilitate viral uptake several
groups have studied DHBV infection in ducklings and primary duck hepatocytes (PDH).
Ideally, one would like to do these studies using HBV in human hepatocytes.
Unfortunately, primary human hepatocytes are poorly available and inefficiently
susceptible to infection using standard culture methods. Viral infections of the duck model
are well-established. Finally, due to the similarity in genome organization and virus
structure among hepadnaviruses it has been assumed that they use comparable mechanisms
to penetrate the host cell.
DHBV expresses two envelope proteins from a single ORF [134]. The hepatocyte
receptor binding domain has been localized to the amino terminal portion of the large (L)
envelope protein, a domain usually referred to as "preS". This domain is not present in the
small (S) envelope protein. The S envelope protein is not essential for infectivity [135].
Different groups have identified a 170kDa (p170) or 180kDa (gp180) glycoprotein
that binds the preS region of the DHBV large envelope protein [127, 136]. This interaction
was shown to be species-specific since the preS region of the HBV large envelope protein
failed to bind p170 [127]. Mutagenesis studies using terminally-deleted preS mutants
revealed that p170 binds to a stretch of amino acids in a highly conserved region in the
preS sequence (aa 87-102) that includes a major neutralizing epitope (site that inhibits viral
replication when masked by antibodies). Others studies with substitution mutations
identified a larger area of the preS region (aa 43-108) as being involved in gp180 binding.
In more recent studies, the apparent conflict was resolved by using surface plasmon
resonance analysis with immobilized DHBV preS polypeptides and soluble duck CPD (aka
gp 180) to demonstrate that within the larger interaction domain (aa 30 -115) of the preS
region that binds gp180 there is a core domain (aa 85-109) that is essential for binding and
an N-terminal region (beginning with aa 30) that stabilizes the gpl80/preS complex [137].
In addition, they also determined a single preS polypeptide binds to a single sdCPD
molecule (1:1) with a dissociation constant, Kd=4.6x10 8M.
Sequencing of a gp180 clone predicts a 150kDa non-glycosylated protein with
thirteen potential sites for N-linked glycosylation [128]. Significant sequence homology
was found between gp180 and members of the basic carboxypeptidase family; particularly
carboxypeptidase H (CPB-H). gp180 is approximately three times the size of CPB-H and
thought to consist of tandem carboxypeptidase homology domains. Basic
carboxypeptidases specifically remove basic amino acids (e.g. lysine, arginine) from the
COOH terminus of polypeptide chains. gp 180 is now designated as duck
carboxypeptidase D (DCPD). Of the three carboxypeptidase-like domains identified
within DCPD, the first and second domains were shown to demonstrate enzymatic activity
[138]. The third domain, which has been shown to be highly conserved (-82%) among the
rat and human homologs of DCPD, is enzymatically inactive but binds the preS region of
DHBV [138].
Various studies give evidence to support DCPD as the host cell receptor for
DHBV. Reconstitution experiments demonstrated that certain cell lines (e.g. 293 (human
embryonic kidney cell line), COS (monkey kidney cells), LMH (chicken hepatoma cells))
transfected with DCPD are able to bind and internalize DHBV particles [139]. However,
no viral replication was observed in DCPD-reconstituted LMH cells which, prior to
reconstitution, are normally permissive for DHBV replication when transfected with
cloned DHBV DNA [139]. Neutralizing antibodies against the DCPD contact site of the
preS region of the viral envelope protein inhibit DHBV binding to DCPD-reconstituted
cells. PreS peptides covering the DCPD binding site were also shown to inhibit DHBV
infection of PDH as well as block DHBV binding to DCPD-reconstituted cells [139].
Antibodies generated against a soluble form of DCPD have been shown to inhibit DHBV
infection in PDHs [140]. However, it was noted that attempts to block infection with
antibodies recognizing only primary sequence elements or denatured soluble DCPD were
unsuccessful. These observations suggest that the tertiary or quaternary structure of the
virus binding site within the receptor is crucial for virus recognition. Breiner et al.
demonstrated that HuH7 cells, which are normally non-permissive for infection,
internalized fluorescein-labeled DHBV particles when transfected with DCPD (via a pUC
plasmid with CMV promoter) [141]. Confocal microscopy revealed that the viral particles
were internalized and in some cases were co-localized with DCPD. None of the cells were
productively infected as determined by the absence of core antigen. In the same study,
they demonstrated that soluble recombinant DCPD (including only the extracellular
domain) is able to inhibit DHBV infection of PDH cultures in a dose-dependent manner.
Finally, DCPD has been detected in both tissues capable of DHBV replication and in
tissues that have shown no evidence of DHBV replication [127, 136].
DCPD has been found on both internal and surface membranes of PDHs [128,
141]. DCPD localizes to an intracellular compartment rather than the cell surface in PDHs
[141]. Further studies using HuH-7 cells confirmed that gpl80 localizes to a Golgi-like
compartment. Further mutagenesis studies identified sequences in the cytoplasmic tail of
DCPD that are involved in its retention in the trans-golgi network or retrieval from the
endosomal-lysosomal pathway [142]. Consistent with its presence in these various
compartments, DCPD has been shown to be active within a broad pH range (pH 5-7).
Aware of other viruses (e.g. measles) that down-regulate their host cell receptors,
Breiner et al. have found that the DHBV L envelope protein specifically down-regulates
DCPD expression in infected hepatocytes [143]. Decreased DCPD expression was found
only in liver and not in other tissues. Pulse-chase analysis demonstrated that DCPD was
being synthesized at similar rates in both infected and uninfected PDHs. In studies done
with HepG2.18 cells (human hepatoma cell line) stably expressing DCPD under control of
CMV promoter investigators also found that expression of the L envelope protein resulted
in a decrease in DCPD steady-state levels, whereas levels of other Golgi-resident proteins
remained unchanged. In their pulse-chase analysis with these L-transfected HepG2.18
cells they found that L envelope protein expression prevented the complete maturation of
DCPD, which led to the accumulation of the precursor (p170), which was subsequently
degraded. gpl80 was localized to perinuclear compartments and occasional small vesicles
in DHBV-infected PDHs that were induced to overexpress gpl80. DHBV L protein
showed a similar cellular distribution in a parallel experiment. According to the authors,
these results support the hypothesis that the DHBV L envelope protein binds gpl80 in a
pre-Golgi compartment, thereby preventing its maturation (leading to degradation). The
down-regulation of the host cell receptor in DHBV-infected cells could serve several
purposes that include preventing gp180 from inappropriately interacting with maturing
progeny virions which have to traffic through the same secretory pathway. Another reason
to down-regulate gp 180 would be to prevent the re-infection of cells that are already
infected.
The aforementioned body of evidence does point to DCPD being necessary for
DHBV susceptibility. However, as mentioned earlier in this section the non-susceptibilty
of DCPD-transduced cell lines that are normally permissive for viral replication indicate
that DCPD is not sufficient to re-establish susceptibility. One possibility is that DCPD is
but one component of a receptor complex that the large envelope protein interacts with on
the host cell surface. One or more additional factors could be necessary to confer DHBV
susceptibility. Another possibility is that DCPD is both necessary and sufficient to
overcome the host specificity constraint and that other liver-specific factors (e.g.
transcription factors) are necessary for the complete viral life cycle to take place. The
following section will review some of the evidence that points to the necessity of a more
differentiated liver phenotype for productive DHBV infection.
1.7.2 Liver Specificity
In terms of other cellular molecules that may be involved in binding DHBV, Li et
al. have identified a 120kDa non-glycosylated protein (p120) that binds cleaved DHBV
preS polypeptides with high affinity [144]. While not proven to occur in vivo, such
cleavages are possible. The p120 binding motif covers a neutralizing epitope and is
conserved among all DHBV strains that have been sequenced. Further importance of p120
binding was established by the reduced infectivity of DHBV with mutations in the preS
region that binds p120. Increasing doses of synthetic preS peptides that bind p120 reduced
DHBV infectivity of PDHs but not as effectively as preS peptides that bind DCPD which
may reflect a sequential interaction with dCPD followed by p120. Finally, the tissue-
specific distribution of p120 matches DHBV hepatotropism. Therefore, depending on the
site of cleavage, p120 may be a component of the receptor complex necessary for DHBV
infection or an intracellular binding partner that aids in disassembly of viral particles.
More recently, Li et al. have confirmed p120 to be the duck p protein component of
the glycine decarboxylase complex (DGD) [145]. Sequence homology, unique binding
patterns to truncated DHBV preS and mutants, and identical tissue distribution established
that p120 and DGD as the same protein. Although DGD is known to reside on the
mitochondrial inner membrane, Li et al. detected it both in the cytoplasm and on the cell
surface using indirect immunofluorescence analysis [145]. Studies have also shown a
correlation between the loss of susceptibility to DHBV and the loss of DGD expression
over time in PDH cultures [146]. Reconstitution experiments in which 17 day-old PDH
cultures were transfected with DGD demonstrated increased viral replication markers (e.g.
DHBV envelope protein, core protein, viral DNA). Antisense RNA was employed in
order to block DGD expression in PDH cultures. The antisense RNA constructs blocked
the translation initiation codon of DGD protein which resulted in reduced levels of
productive infection markers. DGD antibodies that do not interfere with DCPD binding to
the full-length preS domain demonstrated reduced levels of productive DHBV infection
markers. The precise role of DGD during the natural DHBV infection process is yet
unknown but Li et al propose that it might be involved in the proteolytic cleavage of the
viral envelope proteins which is known to occur for many other enveloped proteins within
the lumen of the secretory pathway [146]. Since circulating DHBV particles do not
display processed envelope proteins they suggest that DCPD serves to direct the particles
to the secretory pathway where the large envelope protein may be processed. Following
proteolytic processing the cleaved viral particles may then interact with DGD. However,
recently it has been reported that a DHBV mutant with a point mutation R101H is fully
infectious even though this mutation abolishes binding to DGD [147].
Tang & McLachlan [148] have also identified liver-enriched transcription factors
that support DHBV replication in nonhepatoma cells. Upon transfection of a replication-
competent DHBV genome and various liver-enriched transcription factors it was shown
that the combined expression of HNF3 and HNF4 support viral replication of DHBV DNA
and RNA intermediates. HNF4a is considered to be a master transcription factor due to its
ability to regulate the expression of a disproportionately large number of hepatic genes that
include fatty acid, cholesterol and glucose metabolism, urea biosynthesis, apolipoprotein
synthesis, liver development, and other transcription factors (e.g. HNFla and HNF6) [149-
152]. Multiple genes encoding hepatic and pancreatic enzymes, serum proteins, and
hormones (e.g. glucagon) have been shown to contain HNF3-binding sites. HNF3 has
been shown to play a critical role in the regulation of metabolism and in the differentiation
of metabolic tissues including the liver [153].
To conclude, DCPD is necessary for DHBV infection although the exact role for
this molecule is not completely understood. It has been shown to act as the attachment
receptor which internalizes DHBV particles. Evidence also suggests that there are
additional factors necessary to initiate DHBV infection. Likely candidates include DGD
and HNF4. Our studies (discussed in Chapters 3 and 4) indicate that these factors restrict
DHBV infection to specific tissues but do not necessarily restrict DHBV to a particular
host.
1.8 Objectives & Specific Aims
Hepatocytes rapidly lose liver-specific functions in standard in vitro culture systems.
Loss of susceptibility to Hepatitis B Virus (HBV) infection, a hepatotropic virus, is
attributed to the loss of both the attachment receptor and various liver-specific factors
necessary for viral replication. The main objective of this thesis is to test the hypothesis
that hepatocytes cultured in a more physiological in vitro culture system, that maintains a
more highly-differentiated liver phenotype, remain susceptible to DHBV infection after
extended culture periods. Such a demonstration would provide the foundation for the
future development of a chronic human HBV infection model in which various aspects of
the viral life cycle can be studied and therapeutic targets identified.
DHBV is an ideal virus to employ in this thesis rather than human HBV. Culture
conditions have been established to achieve repeatable DHBV infection in primary duck
hepatocytes. This system has been used to elucidate various aspects of the hepadnavirus
life cycle. One of the most important discoveries is the identification of the host
attachment receptor that internalizes the virus. However, culture of primary duck
hepatocytes requires the addition of factors such as DMSO and hydrocortisone which
maintain a more differentiated state. The mechanism by which these factors bring about
such maintenance is also not completely understood. Combined with practical limitations
of housing ducks, the use of primary duck hepatocytes is not ideal. Fortunately, earlier
studies have demonstrated that freshly-isolated primary rat hepatocytes are capable of
supporting DHBV replication upon transfection of the DHBV genome. Our lab has
extensive experience in maintaining highly-differentiated primary rat hepatocyte cultures
without such additives (e.g. DMSO, hydrocortisone). Therefore, research efforts were
focused on developing strategies to render primary rat hepatocytes susceptible to DHBV
infection.
In order to overcome the species barrier it was necessary to give the rat hepatocyte
the internalization receptor for the DHBV. Recombinant adenoviruses are commonly used
as transgene delivery vectors. Therefore, recombinant adenoviral vectors carrying the
attachment receptor for DHBV were generated. Research efforts focused on characterizing
the transient receptor expression in order to identify the optimal adenoviral concentration
necessary for DHBV infection.
Once cultures were rendered susceptible to DHBV infection it was necessary to
measure evidence of DHBV infection. As discussed earlier in this chapter natural DHBV
infection presents several challenges to studying in an in vitro culture. Factors including
the large ratio of non-infectious subviral particles to infectious Dane particles and the
multiple viral DNA forms present during the infectious cycle required several methods to
be incorporated in order to convincingly affirm active viral replication taking place.
Finally, this thesis will discuss efforts to compare the ability of different culture
systems ability to sustain susceptibility to DHBV infection, once transfected with the
attachment receptor. Following extended culture periods (-2 weeks) primary rat
hepatocytes maintained in the three-dimensional perfused culture system developed in our
lab remained susceptible to infection. This research confirms that after overcoming the
species barrier, primary rat hepatocytes are able to support DHBV replication. This
represents a novel system in which early events in the life cycle (i.e. prior to viral DNA
arriving in the nucleus) can be studied. Extending this research further this system could
be used to study the ability of putative human HBV receptors to initiate viral replication in
a highly-differentiated liver phenotype.
Chapter 2.
Development of 3D Perfused Liver Microenvironment
The ongoing goal of this research group is to develop an in vitro system that
recreates a perfused liver capillary bed structure in order to study different aspects of liver
physiology. To that end, it is necessary to understand the key aspects of the liver
microenvironment that need to be mimicked in an in vitro system.
As mentioned earlier there is an unmet need in the field of HBV research for in
vitro culture systems that maintain a more differentiated liver phenotype. (mention
hepatoma cell lines not being able to be infected) Such a system would facilitate the
dissection of the dynamic virus-cell interactions that are difficult to study in whole animal
models.
The following chapter briefly reviews the development and characterization of the
3D perfused liver microreactor used in this thesis. The key aspects of the liver
microenvironment that will influence the design parameters will be covered.
Comprehensive reviews of the design parameters, fabrication, and characterization of the
multiple reactor systems are available elsewhere [5, 6].
2.1 Key aspects of the liver microenvironment
Like most tissues the liver is composed of multiple cell types that are infiltrated by
blood vessels. As discussed in Section 1.5 signaling that includes direct cell-cell
interactions, cell-matrix interactions, and soluble molecules are necessary to achieve
normal tissue function.
A wide array of models exist that culture the different cell types of the liver
together in various ratios [154-158]. A crucial feature that many of these models fail to
incorporate is physiological perfusion at the length scale of the capillary bed
microenvironment.
2.2 Fostering tissue morphogenesis in vitro
It has been shown that within a mixture of various cell types reorganization into a
functional tissue will occur given the appropriate length scales and time scales [159-161].
Cell adhesion is one of the key processes underlying the way that cells are organized into
tissues. The differential adhesion hypothesis proposed by Steinberg states that when cells
of differing adhesive properties are mixed, stronger, more stable interactions will supplant
weaker interactions resulting in cells separating themselves into different populations [159,
162]. Those with the strongest interactions will aggregate towards the center of the overall
aggregate and the weaker interacting cells accumulating at the surface of the aggregate.
These inherent affinity differences can account for the reorganization of cells and tissues
that have been disrupted and mixed together in culture. Morphogenesis is also affected by
the differential adhesion cell types demonstrate for various matrix substrata.
Predominantly mediated by integrins, cell-matrix adhesion can determine the
reorganization of multiple cells types based on their differential adhesion to the given
substratum present [163].
The design of an in vitro system that fosters the reorganization of dissociated cells
into tissue will require some manipulation of these differential cell-cell and cell-matrix
adhesion properties. The development of this microreactor focused on the manipulation of
homotypic interactions between hepatocytes and the cell-matrix interactions between the
hepatocytes and collagen type I matrix component. The control of heterotypic interactions
between hepatocytes and other cell types found in the liver is not addressed. While these
non-parenchymal cells are present in the prepared cultures it is likely that they are present
at sub-physiological ratios with respect to the hepatocytes. It should also be noted that the
development of this system does not attempt to control soluble signaling mechanisms
either.
2.3 Microscopic design parameters
The central part of the in vitro system is the scaffold (-230pm thick) that contains a
regular array of channels into which the cells are seeded. Each individual channel
represents a functional unit of the microreactor similar to a functional unit of the liver
described earlier (Section 1.3). This scaffold is positioned on a microporous filter that is
mechanically supported by a second scaffold. Tissue morphogenesis is influenced in the
channels of the upper scaffold by several factors that include the adhesion to the channel
walls that are coated with collagen (cell-matrix adhesion), the physical dimensions of the
channels, and the rate of media perfusion through the channel. The microscopic design
parameters are illustrated in Figure 2-1. The cross section of each square channel was set
at 300[tm as an appropriate length scale to allow for cells to reorganize once seeded into
the channels [161]. The depth of the channel (i.e. the thickness of the scaffold) was set at
230ptm in order to mimic the length of the hepatic acinus. The depth was also chosen
based on the ability of oxygen and various nutrients to penetrate the depth of the tissue
using flow rates within the desired operating range. The filter material was used in order
to create a large pressure drop across the filter in order to establish a uniform crossflow of
media through all the channels independent of the differing number of cells and/or tissue
structures present in each channel. The media crossflow rate was chosen to be 50tL/min
in order to meet oxygen demand throughout the depth of the tissue and to simulate
physiological shear stresses . The axial flow was set at 0.5mL/min in order to minimize
oxygen concentration gradients along the length of the scaffold [6].
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Figure 2-1. Diagram of scaffold, microporous filter, and support scaffold. Channel
dimensions were chosen based on several factors that include the length scales over
which cells tend to reorganize, the length of the hepatic acinus, and the ability of
oxygen and other nutrients to penetrate the entire depth of the channel. Flow rates
were set taking into account oxygen demand of tissue within the channels and the
need to stimulate physiological shear stresses.
The fluidic system that was employed is diagrammed in Figure 2-2. It features a
30mL reservoir with a customized lid containing multiple connectors and silicone tubing to
attach the microreactor to the reservoir. Two miniperistaltic pumps were employed in
order to establish the crossflow and the axial flow in the system. Tubing with different
diameter was used in each pump to establish the different axial and crossflow rates.
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Figure 2-2. Schematic of the microreactor and the fluidic system.
2.4 Isolation of primary rat hepatocytes
Figure 2-3 diagrams the procedure used to isolate a population enriched for
hepatocytes. Enriched primary hepatocytes were isolated from male Fischer F344 rats
(150 - 230g) using a modified version of Seglen's two-step collagenase perfusion
procedure [164] as previously described [165]. Tissue dissociation was accomplished
using Liberase Blendzyme 3 (Roche). Final cell viability was > 89% based on trypan blue
exclusion.
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Figure 2-3. Schematic of isolation procedure for hepatocyte-enriched fraction.
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The final cell pellet (-95% hepatocytes) was re-suspended in supplemented DMEM
(GIBCO) that includes 0.03g/L proline, 0.10g/L ornithine, 0.305g/L niacinimide, 2.0g/L
glucose, 2.0g/L galactose, 2.0g/L bovine serum albumin, 0.05mg/mL gentamycin, 5mg/L
insulin, 5mg/L transferrin, 5ug/L sodium selenite, 20ng/mL epidermal growth factor, lmM
L-glutamine, 0.1uM dexamethasone, and trace metals (5.44mg/mL ZnC12, 7.5mg/mL
ZnSO4-7H20, 2.0mg/mL CuSO 4-5H20, 2.5mg/mL MnSO 4) collectively referred to as
Hepatocyte Growth Media (HGM). This medium is a minor modification of the medium
formulation described by Block and coworkers [166].
2.4.1 Formation of spheroidal aggregates
Spheroidal cell aggregates were formed in suspension as previously described
[164]. Briefly, freshly isolated hepatocytes were seeded into a 500mL spinner flask
(BellCo, NJ, USA) at 3x105 hepatocytes/mL HGM and cultured on a spinner table at
84rpm (37oC and 8.5% CO2) to induce spheroid formation. Following a 24h culture
period, 50- to 300-gm spheroids were collected by filtering through 50- and 300-pm nylon
meshes (SEFAR America, Kansas City, MO), pelleting (50xg, 3min), and resuspending in
10 - 15mL HGM. Previous work has shown that a better functional tissue phenotype was
achieved by seeding spheroidal aggregates into the microreactor instead of single cell
suspensions [9].
2.5 Assembly & seeding of the 3D perfused microreactor
The scaffold setup described in Section 2.3 is housed between two polycarbonate
compartments (Figure 2-4). The design and assembly of the microreactor have
been previously described [9, 164]. The assembly protocol used in this thesis is
included in Appendix 1. Following assembly, the microreactor is primed with HGM in
order to passivate all the surfaces in the system and to remove air bubbles from all the flow
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Figure 2-4. A) Schematic of the arrangement of the different components that
constitute microreactor. B) Picture of fully-assembled microreactor. Images
taken from [6].
paths in the systems. In order to seed the spheroidal aggregates into the fully assembled
microreactor a 1-mL syringe was connected to the outlet port of the upper chamber
(port#l) (Figure 2-4b) and the peristaltic pump was activated in order to fill the syringe
with -ImL of HGM. A syringe filled with 1-mL of filtered spheroidal aggregates was
connected to the inlet of the upper chamber (port#4). The cross-flow tubing was
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unclamped and then the spheroid suspension was manually injected into the upper chamber
of the microreactor slowly (-0.5nmLmin). The spheroidal aggregates go into the channels
through a combination of settling and flow of HGM from the upper chamber into the lower
chamber. Once the channels are full the resistance to flow in this direction becomes
greater than the resistance provided by the syringe attached to the outlet and the piston of
the syringe will begin to move. Both syringes are removed and the tubing is reconnected
and the media is set to flow in a downward fashion, from the upper chamber to the lower
chamber. After lh, the HGM in the media reservoir is replaced with fresh HGM in order
to remove residual cells and cellular debris from the system. Flow rates were chosen based
on simulating physiological sheer stress conditions and satisfying tissue oxygen demand
(as discussed in Section 2.4). A detailed seeding protocol is provided in Appendix 2.
2.6 Evaluation of the hepatic phenotype in the 3D perfused microreactor
In order to determine the capability of the 3D perfused microreactor to maintain a
well-differentiated liver phenotype in vitro it is necessary to characterize various aspects of
the liver phenotype such as biochemical production (e.g. albumin secretion), tissue
morphology, mRNA expression, and drug metabolism. Such analysis has been published
elsewhere [9, 10]. The remaining portion of this section will summarize some of the key
findings.
2.6.1 Analysis of albumin and urea secretion
Earlier work was done in the group to evaluate liver-specific function in the
microreactor media samples from the reservoir were assayed for both serum albumin and
urea[6, 9, 10]. Serum albumin concentrations were determined by a sandwich enzyme-
linked immunosorbent assay (ELISA) [167]. Urea concentrations were measured by
Berthelot determination methods (urea nitrogen kit from Sigma, procedure 640. Both the
albumin and urea data were normalized to total DNA measured in the microreactor. These
analyses revealed a long-term microreactor albumin secretion rate of -~150pg/cell/day and
urea synthesis rate of -700-900 pg/cell/day for reactors seeded with spheroidal aggregates.
These rates are an order of magnitude higher than comparable static cultures [9].
2.6.2 Tissue morphological analysis
Figure 2-5 shows representative transmission electron micrographs (TEM) of fixed
microreactor tissue sections. One will note the presence of cell-cell junctions and bile
canaliculi. As discussed in Section 1.5 it is the loss of such cell-cell interactions that are
involved in the loss of liver function in standard culture. Their presence in the
microreactor during extended culture indicates some success in recapitulating liver
structure.
Figure 2-5. Transmission electron micrographs (TEMs) of tissue structures formed in
microreactor channels. Left image shows a series of canaliculi bound by desmosomes
(arrowheads) between adjacent hepatocytes. Right image includes a large bile
canalicula containing microvilli (large arrows) located at junction of three hepatocytes
and bounded by tight junctions (small arrows). MT = mitochondria, BC = bile
canaliculi. Images taken from [9].
Figure 2-6 includes representative scanning electron micrographs in which endothelial-like
cells are located at the tissue-fluid interface in the channel. Such organization is
suggestive of the sinusoidal environment, wherein endothelial cells form the porous walls
of the sinusoid (described in Section 1.4.2), through which blood travels.
Figure 2-6. Scanning electron micrographs of tissue structures formed in microreactor
channels.
00
Cell viability within the microreactor was assessed using a Calcein AM-ethidium
homodimer stain (Figure 2-7). The Calein AM (green fluorescence) is actively taken up by
live cells while ethidium homodimer (red fluorescence) is only able to penetrate dead cells.
These long-term (13 days) microreactor cultures demonstrate that the majority of the cells
are still viable. There has also been significant tissue reorganization considering that these
cultures were seeded with spheroidal aggregates.
Figure 2-7. Live-dead cell images in the microreactor. Calcein AM-ethidium
homodimer stain of cells maintained in microreactor for 13 days. Channel width =
300tm.
2.6.3 Liver-enriched mRNA & protein expression
It was mentioned in the previous chapter (Section 1.4.1) that detoxification is
among the many vital functions performed by hepatocytes. The conversion of foreign
chemicals (e.g. drugs, toxins) into more water-soluble forms (a.k.a. biotransformation)
allows them to be removed from the organism (via feces or urine) requires many enzymes.
Although present in various tissues these enzymes are highly concentrated in the liver.
Earlier work done in the group focused on the expression of cytochrome p450 (CYP450)
enzymes, a system of enzymes that are responsible for the biotransformation of a wide
variety of foreign chemicals. RT-PCR analysis revealed that among the genes for enzymes
studied (including CYP450s) most of them were either unchanged or only slightly down-
regulated in the microreactor after 7 days in culture. By comparison, collagen gel
sandwich culture (a static 2D culture) demonstrated strong down-regulation for the same
genes. Studies looking at particular CYP protein activity (e.g. rates of testosterone
hydroxylation) found trends similar to those at the mRNA level such that the microreactor
cultures can maintain activity levels closer to physiological levels than conventional 2D
cultures [10].
mRNA data was also collected for various key transcription factors. As discussed
in the previous chapter (Section 1.5) the loss of the differentiated liver phenotype is a
result of changes in gene expression and diminished transcription of liver-specific genes.
Many liver-specific genes, including the CYP450s, contain multiple consensus Hepatocyte
Nuclear Factor (HNF) binding sites [168, 169]. Therefore, a differentiated liver phenotype
requires the expression of multiple HNF transcription factors. Previously published
studies in our group used RT-PCR analysis to demonstrate that the expression of multiple
HNFs remained unchanged in the microreactor [10]. However, significant down-
regulation was observed in the collagen gel sandwich cultures for those same HNFs.
HNF4a is considered to be a master transcription factor due to its ability to regulate the
expression of a disproportionately large number of hepatic genes that include fatty acid,
cholesterol and glucose metabolism, urea biosynthesis, apolipoprotein synthesis, liver
development, and other transcription factors (e.g. HNFla and HNF6) [149-152]. It was
demonstrated that in microreactor cultures HNF4a is better maintained over seven days at
both the mRNA and the protein level than in collagen gel sandwich culture.
2.7 Scaling up the microreactor
Each individual channel of the microreactor represents a functional unit. Different
experimental applications may require greater cell numbers or multiple treatment
conditions. To meet these needs efforts have gone into scaling up the microreactor system
by 1) increasing the number of channels in the microreactor scaffold and 2) developing a
high-throughput format that would allow multiple microreactors to be operated in parallel
(i.e. simultaneous dosing of twelve different microreactors with separate compounds). In
the following section the development and characterization of these two different scaled up
systems are reviewed.
2.7.1 Development of the giant microreactor
The micoreactor described in these earlier sections of this chapter was designed to
maintain liver cells in long-term 3D culture that could be assessed via in situ optical
imaging and spectroscopy for structure and function. This system can hold -100,000 cells
at maximum capacity. However, some applications (described in later chapter) will require
greater cell numbers. By keeping the microenvironment constant (i.e. the channel
dimensions and flow rates) the system can be scaled up by adding more channels in the
overall array on the scaffold. Such a system was developed and the details of its design
and fabrication are available elsewhere [7].
The giant microreactor contains one-thousand 300x300x230tm square channels in
the scaffold as compared to forty such channels in the previous microreactor (Fig 2-8).
These additional channels allow the giant microreactor to culture x 106 cells which will
satisfy the sensitivity requirements of various assays described in later chapters. Flow
rates (using the same dual pump fluidic set up) were linearly scaled up in order to maintain
the same per channel flow and residence time in the upper chamber as in the earlier model.
For a detailed assembly, seeding, and maintenance protocol please see Appendix 3.
Figure 2-8. Giant microreactor. In this scaled up model there are a total of
1000 channels (300x300x230[tm) which will hold -1x106 cells upon seeding.
While the components for the giant reactor are similar to the earlier model there are
some key differences in working with the giant reactor. In the earlier model silicon
worked well as the scaffold material. However, in the giant microreactor silicon presented
a number of disadvantages. Fabrication of silicon scaffolds for the giant microreactor was
costly and tedious because only 2 scaffolds could be machined at the same time. The top
cell-containing scaffold and the bottom support scaffold must be perfectly aligned in the
assembled microreactor in order to insure uniform flow through the channels. Therefore,
the scaffolds were machined to exactly fit the dimensions of the pocket in the middle
polycarbonate microreactor compartment. Inserting the scaffolds into the pocket proved
difficult and would result in either breaking the scaffolds or significantly extending the
assembly time. Polycarbonate proved to be a suitable scaffold material. Drilling methods
were developed by Jim Serdy to fabricate circular channels with a 300tm diameter (to
allow for cell sorting). Additional changes including increased tubing diameter, additional
filters in the crossflow line, different geometries at the inlet and outlet ports of the
microreactor are discussed in detail elsewhere [7].
2.7.2 Characterization of the giant microreactor
To characterize the ability of the giant microreactor to foster an in vivo-like liver
phenotype both tissue morphology and gene expression were studied. These studies would
also allow a comparison of this scaled up system to the earlier model. Tissue morphology
was evaluated via light microscopy. As shown in Fig 2-9 tissue structures formed by day
14 are comparable to those seen in the earlier microreactor system.
Figure 2-9. Phase contrast image of tissue structures in channels of giant microreactor.
Spheroids (24h in spinner flask) were seeded into the channels. 5x objective
A number of liver-specific genes were analyzed by real-time RT-PCR and
compared across multiple cultures that included in vivo liver slices, isolated hepatocytes,
2-D collagen gel sandwiches, milliF microreactor, and the giant reactor. In Fig 2-10 the
relative gene expression levels revel that the giant microreactor and the milliF microreactor
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Figure 2-10. Relative gene expression across culture systems. Real-time RT-PCR
analysis was used in order to measure gene expression in different culture systems and
compare it to gene expression within in vivo liver slices. The baseline represents the
gene expression of in vivo liver slices. Figure taken from [7].
display similar expression patterns with a few exceptions [7]. Both systems showed better
maintenance of gene expression than the 2-D collagen gel sandwich cultures. This
indicates that the changes made in order to scale up the microreactor did not significantly
alter the microreactor's ability to maintain a more in vivo-like liver phenotype.
2.7.3 Development of the multi-well microreactor
A newer generation microreactor has been developed in the Griffith laboratory that
builds on earlier models. Whereas earlier models employed 2 relatively bulky peristaltic
pumps to generate the necessary fluid flow the latest model uses significantly smaller
pneumatic pumps which allow multiple microreactors to be fabricated on a single 24-well
standard tissue culture plate format. This newer generation (a.k.a. multi-well microreactor)
represents a more high-throughput system in which 12 micoreactors, each capable of
culturing -800,000 cells, are fabricated on a single plate.
The reactor is a multilayered structure whose design and assembly have been
previously described (Fig 2-11) [170].
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Figure 2-11. Multi-well microreactor diagram. A) Fully assembled micoreactor
with controller for pneumatic pump connected. B) Image of individual reactor unit.
C) Cross-sectional diagram of scaffold assembly. Images taken from [5].
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Briefly, there are 12 reactor units on a single fluidic plate. Each reactor unit consists of a
scaffold assembly and a media reservoir. The polycarbonate scaffold has an array of 800
circular channels (diameter = 300[tm, depth = 230tm). Cells in the scaffold channels are
continuously perfused with culture media from the reservoir via a pneumatic pump which
is then recirculated across a surface channel back to the reservoir (Figure 2-11 lb). Each
reactor unit is fluidically isolated but all pumps are simultaneously driven by pneumatic
control lines connected to sources of positive and negative air pressure. Physiological
rates of media perfusion are achieved by controlling the frequency of the pulses of air
pressure. Primary scaffold channels are coated with collagen type I (30pg/mL) to allow
for cellular attachment.
The greatest advantage of the multi-well microreactor is the relative ease by which
several reactor units can be manipulated. This allows various parameters such as multiple
dosing concentrations to be studied in the same experimental setup and therefore
minimizes animal-to-animal or instrument variation. A detailed discussion of the
assembly, seeding, and maintenance is available elsewhere [171]. The protocol used in
this thesis is available in Appendix 4.
2.7.4 Characterization of multi-well microreactor
Relative gene expression data indicate that the multi-well behaves similarly to the
earlier microreactor system (Fig. 2-12, [5]). The genes being measured include those that
transcribe Phase I and Phase II enzymes, surface proteins, and transcription factors.
Overall, the milliF, giant, and multi-well microreactor systems demonstrate similar gene
expression profiles.
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Figure 2-12. Relative gene expression analysis in multi-well. 72h spheroids were seeded
into multi-well ("bioreactor"). This data represents day 7 post cell isolation gene expression.
Expression levels are normalized to freshly isolated hepatocytes. Taken from [51.
The incorporation of single cell seeding immediately following the perfusion was
revisited. Earlier studies done in the milliF had demonstrated that spheroidal cell
aggregates performed better over the length of the culture [164]. As shown in Figure 2-13
phase contrast and live-dead staining indicate healthy tissue structures present by 5 days in
culture. Relative gene expression data (Fig. 2-14, [5]) confirm that single cells perform
similarly to spheroidal aggregates and represent a viable option when seeding the multi-
well microreactor. Further characterization of drug metabolism via metabolite
accumulation and specific p450 induction is available elsewhere [5].
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Figure 2-13. Tissue structures formed after 5 days in culture in multi-well microreactor.
Calcein AM-ethidium homodimer stain indicates good cell viability that is comparable to
viability measured in earlier microreactor system. These are silicon scaffolds with square
channels (300x300x230[tm). Images courtesy of Dr. Sharon Karackattu.
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Figure 2-14. Comparison of relative gene expression levels in multi-well cultures seeded with
either single cells or 72h spheroids. Data represents day 7 post cell isolation. Taken from [5].
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Chapter 3.
A Novel Method to Render Primary Rat Hepatocytes
Susceptible to Duck Hepatitis B Virus
3.1 Introduction
Human HBV is the prototype member of the family Hepadnaviridae that consists
of enveloped, partially double-stranded DNA viruses that specifically target hepatocytes
for viral replication [111]. Although a vaccine has been available for more than 20 years
chronic hepatitis B afflicts -5% of the world's population [11]. All hepadnaviruses display
a narrow host range. Besides humans, chimpanzees and, more recently, Tupaia belangeri
tree shrews are the only animals that are susceptible to infection [11, 111]. The use of
primary human and primate hepatocytes is restricted by multiple experimental limitations
including a rapid loss of susceptibility to infection in culture, lot-to-lot variability in
susceptibility to infection, and the necessity of treatment with chemical agents such as
DMSO for reproducible infection [107, 108, 120]. There is also low efficiency of HBV
infection in primary human and Tupaia belangeri hepatocytes [117, 172]. Along with the
lack of susceptible cell lines or small animal models these factors have hampered research
into many aspects of hepadnavirus biology.
Permissive cell lines (e.g. HepG2, Huh7), capable of supporting viral replication
upon transfection with the viral genome, have shed greater light on the later events in the
viral life cycle (i.e. transcription, encapsidation reverse transcription, virion assembly,
export). However, there is less understanding of the early stages that include virus
attachment, internalization, uncoating, genome repair, and nuclear transport. These cell
lines do not mimic natural infection which limits their usefulness. An in vitro system that
will allow us to target other aspects of the viral life cycle is needed.
Similar genome organization, virus structure, and replication characteristics among
hepadnaviruses warrant the study of hepadnaviruses found in other species. Many of the
principles of hepadnavirus life cycle were elucidated by studying duck hepatitis B virus
(DHBV) as a model for HBV. Elucidated principles include the replication by reverse
transcriptase [125], cccDNA formation [126], and host-range determinants [127-129].
However, reproducible in vitro infection of primary duck hepatocytes requires culture
conditions that incorporate 1.5-2% DMSO whose mechanism of action is unknown [130,
131]. Even with such artificial additives the kinetics of in vitro infection are slow and
inefficient when compared to in vivo infection of neonatal ducklings [132].
Putative host receptors for DHBV have been defined. The amino terminal portion
of the large envelope protein (preS domain) has been shown to be involved in virus uptake
[136, 173]. Studies have demonstrated that hepatocyte penetration of DHBV occurs via
the attachment of a highly conserved region in the preS domain to an enzyme known as
carboxypeptidase D (cleaves C-terminal basic residues) [128, 136, 141, 174]. Current
evidence from multiple groups has shown that DCPD serves a crucial role in DHBV
infection: 1) reconstitution experiments demonstrate that permissive cell lines (e.g. LMH
cells) transfected with DCPD are able to internalize DHBV particles; 2) recombinant
DHBV preS peptides covering the DCPD binding site inhibit DHBV infection of PDH as
well as block DHBV binding to DCPD reconstituted cells; 3) soluble recombinant DCPD
(including only the extracellular domain) is able to inhibit DHBV infection of PDH
cultures in a dose-dependent manner; 4) antibodies against DCPD block DHBV infection
5) DCPD expression is specifically downregulated in DHBV-infected hepatocytes and not
in other tissues 6) reconstitution of PDH with DCPD mutants lacking the cytoplasmic
TGN-retrieval signal abolishes DHBV infection in those cells. However, it has not been
possible to render non-susceptible cell lines that fully support DHBV replication after
transfection with cloned DHBV DNA susceptible via DCPD expression. DCPD is also
found on tissues not susceptible to DHBV infection [136]. Taken together these data
suggests that either there are additional host-specific factors necessary or that there are
tissue-specific factors that only exist in a more highly differentiated state.
We report here the use of recombinant adenovirus vectors to transfer DCPD to
primary rat hepatocytes in order to study the ability of a normally non-susceptible species
to support DHBV replication. Earlier studies have shown that primary rat hepatocytes are
capable of supporting DHBV replication upon adenoviral transfection of the viral genome,
confirming that the later events of the viral life cycle are not rigidly host-restricted [175].
We generated recombinant vectors in which both DCPD and green fluorescent protein
(GFP) are incorporated in the adenoviral genome. DHBV replication was initiated in
primary rat hepatocytes when DCPD was transduced via adenoviral delivery. In this study
we provide the first evidence that DCPD is sufficient to cross the species barrier and
establish a DHBV infection in primary rat hepatocytes. We also report DCPD transduction
in primary rat hepatocytes cultured in a microfluidic device that promotes a more highly-
differentiated liver phenotype than conventional culture systems (e.g. collagen-coated
polystyrene, collagen gel sandwich).
3.2 Materials and Methods
3.2.1 Primary rat hepatocyte isolation and culture
Primary liver cells were isolated from male Fischer rats (150 - 230g) using a
modified version of Seglen's two-step collagenase perfusion procedure [164] as previously
described [165]. Tissue dissociation was accomplished using Liberase Blendzyme 3
(Roche). Final cell viability was in the range of 89-94 % based on trypan blue exclusion.
The final cell pellet (-95% hepatocytes) was re-suspended in supplemented DMEM
(GIBCO) that includes 0.03g/L proline, 0. 10g/L omithine, 0.305g/L niacinimide, 2.0g/L
glucose, 2.0g/L galactose, 2.0g/L bovine serum albumin, 0.05mg/mL gentamycin, 5mg/L
insulin, 5mg/L transferrin, 5ug/L sodium selenite, 20ng/mL epidermal growth factor, ImM
L-glutamine, 0. luM dexamethasone, and trace metals (5.44mg/mL ZnC12, 7.5mg/mL
ZnSO 4-7H 20, 2.0mg/mL CuSO 4-5H20, 2.5mg/mL MnSO 4) collectively referred to as
Hepatocyte Growth Media (HGM). This medium is a modified version of that described
by Block et. al. [166]. Resuspended hepatocytes were plated on polystyrene plates coated
with collagen type I (30 tg/mL) (BD Biosciences) at a plating density of 50,000 cells/cm 2.
Cultures were maintained at 37'C and 5% CO 2 with media changes every 48h.
3.2.2 Multi-well microreactor culture
A schematic of the reactor and fluidic circuit is shown in Figure 1. The reactor is a
multilayered structure whose design and assembly have been previously described [170].
Briefly, there are 12 reactor units on a single fluidic plate. Each reactor unit consists of a
scaffold assembly and a media reservoir. The polycarbonate scaffold has an array of 800
circular channels (diameter = 300tm, depth = 230tm). Cells in the scaffold channels are
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Figure 3-1. Diagram of multi-well microreactor. A) Image of microreactor
connected to controller device for pneumatic pumps. B) Image of individual reactor
unit consisting of media reservoir and a reactor well containing the scaffold assembly
which is connected by a surface channel and a pneumatic pump. C) Illustration of
scaffold assembly with tissue in channels. Taken from [5].
continuously perfused with culture media from the reservoir via a pneumatic pump which
is then recirculated across a surface channel back to the reservoir. Each reactor unit is
fluidically isolated but all pumps are simultaneously driven by pneumatic control lines
connected to sources of positive and negative air pressure. Physiological rates of media
perfusion are achieved by controlling the frequency of the pulses of air pressure. Primary
scaffold channels are coated with collagen type I (30[tg/mL) to allow for cellular
attachment. Prior to seeding, the microreactor system is primed with HGM in order to
passivate the surfaces and remove any air bubbles in the fluidics. Primary cells isolated
from the rat perfusion are pipetted directly into the channels of the scaffold and adhere to
the collagen coating the channel walls. During the first 8h the media perfuses the channels
in a downward direction in order to pull the cells into the channels. To eliminate any
residual cell debris that might clog the filter the media flow is reversed (lower chamber to
upper chamber) after 8h and fresh media is added to the reservoir. Reactors were
maintained at 370C and 5% CO2 with daily media changes.
3.2.3 Generation of recombinant adenovirus vectors
The adenovirus constructs were generated using the AdEasy vector system and has
been previously described [146]. Briefly, a shuttle vector containing the gene of interest
(DCPD) and an adenovirus backbone plasmid that includes the Ad5 genome with both El
and E3 genes deleted were co-transformed into an E. coli strain (BJ5183). The highly
efficient homologous recombination machinery within the bacteria produce recombinant
adenovirus constructs containing the gene of interest. These constructs are linearized and
transfected into the 293 packaging cell line which constitutively express El gene products,
necessary for propagation of all recombinant adenoviruses. Successful viral production is
monitored via the GFP reporter gene which is also incorporated into the adenovirus
backbone plasmid. Further tests were done to confirm that there were no replication-
competent adenovirus constructs present in the final preparations. The final recombinant
adenovirus containing the DCPD gene is designated Ad-eGFP-DCPD. This vector was
kindly provided by the Wands laboratory at Brown University. Further amplification and
purification was performed by Puresyn, Inc.
3.2.4 DHBV-positive serum isolation
Mammoth White Pekin ducklings were obtained from a commercial supplier
(Ridgway Hatchery), housed at the Liver Research Center at Brown University, and given
ad libitum access to food and water. Three-day old ducklings were injected in a foot vein
with 200uL of highly viremic duck serum. Five days later the duck was sacrificed by
pentobarbital overdose (Abbott Laboratories) and the total blood volume was collected via
cardiac puncture. Total blood was kept at room temperature for -6hrs and then spun (3000
rpm) for 5 min. The serum was collected and tested for DHBV particles via dot blot
analysis. Briefly, total DNA was isolated using QIAamp DNA MicroKit (Qiagen), boiled
at 100C for 10 min and placed immediately on ice. DNA was spotted onto nylon
membrane (Schleicher & Schuell) and fixed using UV exposure. A 32P-radiolabeled
DHBV DNA probe was added overnight (45C). Following multiple washes, the blot was
exposed to a phosphor screen that was developed on a Cyclone Imaging Station (Packard
Bioscience).
3.2.5 DHBV infection
Approximately 6h after plating, cultures were exposed to adenovirus vectors
diluted in HGM to achieve the proper multiplicity of infection (MOI). Cells were cultured
with the adenovirus for -24h at 37C prior to being removed with multiple washes of
Phosphate Buffered Saline (PBS). DHBV-positive duck serum was diluted (1/5) in HGM
and added to the cultures for 24 incubation at 37C. The diluted serum contained -
7.2x108 virus genome equivalents (vge)/mL as determined by PCR analysis. Non-
adsorbed virus particles in the culture were removed with multiple PBS washes. Cells
were maintained at 37C with media changes every 48h.
3.2.6 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and
western blot analysis
Cell samples were lysed with 100uL RIPA buffer on ice for 20 minutes and total
protein was determined by BCA protein assay (Pierce). SDS-PAGE was done using 7.5 or
12% polyacrylamide gels (BioRad). Prior to loading the gel, samples were adjusted so that
equal amounts of total protein were loaded onto the gel. Following electrophoresis,
proteins were transferred to a polyvinylidene difluoride (PVDF) membrane (BioRad,
USA). The PVDF membrane was probed with primary antibodies that included:
polyclonal rabbit anti-duck carboxypeptidase D (1:10000 dilution), polyclonal rabbit anti-
DHBV preS (1:5000 dilution) and rabbit polyclonal anti-actin (1:10,000 dilution) (Santa
Cruz). Primary antibodies were detected with goat anti-rabbit HRP-conjugated secondary
antibody (1:5000 - 1:10000 dilution) (Jackson Immunoresearch, USA). Detection and
quantification were done using enhanced chemiluminescence (ECL) (Amersham, USA)
and a Kodak Image Station (Eastman Kodak).
3.2.7 Isolation and detection of DHBV DNA in primary rat hepatocytes
Cell samples were analyzed for the presence of DHBV DNA as previously
described [175]. Briefly, samples were lysed in TEN Buffer (150mM NaCl, 50mM Tris-
HCl (pH 8.0), 10mM EDTA, 1% SDS) and 0.5mg/mL proteinase K overnight at 37C.
Residual protein was removed via phenol-chloroform extraction.
Nucleic acids were precipitated using ethanol and dissolved in TE buffer. Nucleic
acid samples were subjected to electrophoresis in a 1% agarose gel. DNA was fragmented
with 0.25N HCl-0.6M NaCl, denatured with 0.5N NaOH-1.OM NaCl, and neutralized with
1.OM Tris-HCl (pH 7.0)-1.0M NaCl. Samples were then transferred to a nylon membrane
overnight at room temperature. Hybridization was done overnight at 42C using a nick-
translated 32P-labelled DHBV probe (MegaPrime DNA Labelling System, Amersham
Biosciences). The blot was exposed to x-ray film with an intensifying screen (Biomax,
Eastman Kodak Co.) for 72h at -80C. The film was developed on an X-OMAT 100A
processor (Kodak).
3.2.8 Fluorescence Activated Cell Sorting (FACS) analysis.
After plating, hepatocytes were exposed to adenovirus at different MOI for -24h.
Non-adsorbed particles were washed out with multiple PBS washes. Several samples were
collected using 10mM EDTA and fixed in 2% paraformaldehyde. Other samples were
exposed to DHBV serum diluted in HGM (-3x108 vge) for -24h. Following multiple PBS
washes to remove nonadsorbed DHBV particles the samples were collected using dispase
(50U/mL, BD Biosciences) and fixed in 2% paraformaldehyde. Some fixed cell samples
were permeabilized using ice cold 100% MeOH. Samples were blocked with 1% bovine
serum albumin for 1 h and then exposed to primary antibodies that include polyclonal
rabbit anti-duck carboxypeptidase D (1:250 dilution) and polyclonal rabbit anti-DHBV
preS (1:250 dilution). Primary antibodies were detected with highly cross-adsorbed goat
anti-rabbit AlexaFluor 647 secondary antibody (1:250 dilution) (Invitrogen). Labeled cells
were analyzed using a FACSCalibur dual laser flow cytometer system (BD Biosciences).
3.2.9 Fluorescence & Immunofluorescence analysis
Cultures maintained on collagen-coated polystyrene dishes were imaged using a
Zeiss Axiovert 100 microscope. GFP expression was imaged using a fluorescein
isothiocyanate (FITC) filter. To analyze DCPD expression in the tissue structures formed
in the multi-well cultures, cells were fixed in 2% paraformaldehyde and permeabilzed
using 0.1% Triton X-100. Following a 1h incubation in normal goat serum (1:20 dilution)
the rabbit anti-duck DCPD Ab was added overnight at 4C (1:1000 dilution). Alexa Fluor
568-conjugated highly cross adsorbed goat anti-rabbit secondary antibody (Invitrogen) was
incubated with the cells for lh at room temperature. Confocal images were collected using
a Nikon TE2000 microscope equipped with a Yokagawa spinning disk confocal head
(McBain Instruments) and processed using Metamorph Offline 6.1r0 software.
3.2.10 Statistical analysis
Statistical significance of results was analysed using GraphPad Prism Version 4.0
for Windows (GraphPad Software, San Diego, CA). One-way analysis of variance
(ANOVA) tests were used to compare mean cell numbers present at a given timepoint for
increasing adenovirus concentration. The difference in means was considered statistically
significant when probability values were <0.01.
3.3 Results
3.3.1 DCPD expression in primary rat hepatocytes (PRH) in standard tissue culture
Following plating on collagen I-coated tissue culture plates, replicate PRH cultures
were exposed to Ad-eGFP-DCPD at select MOI ranging from 0-50. Recombinant
adenoviral infection is known to cause transient transgene expression. Fluorescence
images were taken every 24h for 5 days to follow GFP expression. At the initial timepoint
(24h following Ad exposure), GFP expression can only be observed at the higher MOI
(MOI 20, 50) (Fig. 3-2a). By 48h in culture significant cell spreading has occurred in all
conditions and cultures appear to be confluent. Increasing transfection efficiency is
observed for increasing Ad MOI. Individual cells within each condition appear to exhibit
different GFP intensities indicating the possibility of differential adenovirus uptake and/or
differential protein translation capability. By 72h in culture GFP intensity has reached a
maximum level. Some cell death is observed in the MOI=50 cultures but all lower MOI
are comparable to the control (No Ad) cultures. By 96h the percentage of GFP-positive
cells have declined in all MOI conditions. Similar percentages seen at 120h suggest that a
baseline level of GFP expression is being observed.
The expression of DCPD was investigated by western blot analysis (Fig. 3-2b).
Following Ad-eGFP-DCPD MOI=10 exposure, relatively equal levels of DCPD
expression were measured over 9 days in culture. Equal loading of total protein in the blot
suggests that cells being lost over the culture period were not expressing significant DCPD
or that DCPD expression increases over time in order to compensate. Western blot
analysis also established that increased DCPD expression is achieved by exposure to
increased Ad MOI. This analysis demonstrates DCPD maintenance for -2weeks.
It is interesting that DCPD appears as two separate bands (Fig. 3-2c) which has
been observed in primary duck hepatocyte cultures [141]. This doublet could represent the
membrane-bound form (180kDa) and a truncated form (170kDa). Another group showed
that upon transfection with DCPD (via baculovirus expression vectors) insect Sf9 cells
secreted a soluble 170kDa version that behaved similarly with regard to enzymatic activity,
activation, and optimum pH [138]. It was suggested that the 170kDa version was likely
missing the putative transmembrane domain and cytoplasmic tail because it does not react
strongly with an antiserum raised against the C-terminal tail. It was concluded that such a
truncation resulted either from proteolysis or from differential mRNA splicing. A variety
of smaller versions of carboxypeptidase D (CPD), some of which are soluble, have been
observed in both bovine and rat tissues [176]. It is interesting to note that for lower Ad
MOI (MOI=2) there appears to be a loss in the truncated form of the DCPD over time in
culture. For the higher Ad MOI (MOI=5, MOI=10) both forms are present for -2weeks.
At 72h following Ad exposure, parallel PRH samples were fixed in 2%
paraformaldehyde in order to analyze DCPD expression on an individual cell basis via
FACS analysis. DCPD is located both intracellularly and on the plasma membrane and it
has been shown to traffic back and forth from the trans-Golgi network (TGN) to the cell
surface [177]. Half of the fixed samples were permeabilized to determine the total (surface
& intracellular) levels of DCPD. As expected, greater levels of DCPD are detected in
primary rat hepatocytes infected with increasing Ad MOI (Fig 3-3a). Comparing
permeabilized hepatocytes and non-permeabilized hepatocytes for a given Ad MOI it
appears that the majority of the DCPD (> 70%) is available on the cell surface (Fig. 3-3b,
Table 3.1). Previous studies using CPD-transfected AtT-20 cell line (murine pituitary
tumor) have shown that a small fraction (-10%) of CPD is available at the cell surface
[178, 179]. Mutational analysis in these earlier studies demonstrated that a cytoplasmic
domain functions in TGN retention inside cell compartment.
It is interesting to note that for increasing Ad MOI a growing subpopulation
appeared that is negative for GFP expression but positive for DCPD expression. This
could explain the apparent discrepancy between timecourse expression of GFP and DCPD
seen in Figure 3-2. This DCPD+/GFP- population could account for the sustained DCPD
expression. As mentioned earlier the two transgenes carried in the adenoviral vector
(DCPD and GFP) are contained within two independent CMV-driven transcription units.
Differential translational and post-translational regulation may account for the two distinct
subpopulations. Comparing the permeabilized vs non-permeabilized DCPD within this
particular population also indicates that the majority of the DCPD ( .50%) is available on
the cell surface.
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3.3.2 DCPD protects against Ad-mediated cytotoxicity
A striking morphological difference was consistently observed between cultures
exposed to control vectors (Ad-e or Ad-eGFP) compared to the Ad-eGFP-DCPD vectors
(Fig. 3-4). Control Ad vectors appeared more toxic at moderate MOI (MOI =5, MOI=10,
MOI=20) than did Ad-eGFP-DCPD vector as assessed by substantial number of cells with
a condensed apoptotic appearance (Fig. 3-4b, 3-4c, 3-4d, 3-4e). The apparent toxicity seen
in light micrographs was quantified by measurement of total protein as an indicator of cell
number. Statistical analysis revealed that cell loss over the 5-day culture period was
significantly greater in cultures exposed to Ad-e MOI=50, Ad-eGFP MOI=20, Ad-eGFP
MOI=20, and Ad-eGFP MOI=50 than the control, no Ad, case at the later timepoints (72,
96, and 120h) (p values <0.01) (Fig. 3-4f, 3-4g). In contrast no significant cell loss greater
than the control (no Ad) case was observed for any of the PRH cultures exposed to any
Ad-eGFP-DCPD MOI (Fig. 3-4h). Adenovirus-mediated toxicity is a well-known
phenomenon. Underlying mechanisms include adenovirus-mediated sensitization to TNF-
induced apoptosis [180]. The PRH cultures in our study are enriched for hepatocytes but
-5% of the culture consists of NPCs that include macrophages which can efficiently take
up adenovirus and subsequently release TNF to eliminate surrounding infected cells in an
inflammatory response. Earlier work has shown that upon infection E1/E3-deleted
adenovirus vectors can still cause low level expression of other wild-type gene products
such as E4 that can induce apoptosis [181]. Such mechanisms are likely to be involved in
the cell loss observed in these experiments. Ad-e and Ad-eGFP stock preparations have
nominal ratios of non-infectious to infectious units of 11:1 and 12:1, respectively, while
Ad-eGFP-DCPD stock preparation has a ratio of 6:1. As demonstrated in Figure 3-5a and
3-5b the observed cell loss in Ad-e and Ad-eGFP can not be solely explained by
differences in total virus particles. It appears that expression of DCPD protects cells
against adenovirus-mediated toxicity, a result not previously reported in the literature.
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Figure 3-4. DCPD protects against adenovirus-mediated cytotoxicity. A)-E) Phase-contrast
and GFP expression images of PRHs following Ad exposure (24h, 48h, 72h, 96h, 120h). Total
protein values were determined following adenovirus exposure. F) PRHs exposed to Ad-e
vectors. G) PRHs exposed to Ad-eGFP vectors. H) PRHs exposed to Ad-eGFP-DCPD
vectors. Data represents mean ± SD of 2 biological replicates (2 technical replicates per
biological replicate). * P <0.01, significantly different from No Ad control.
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Figure 3-5. Differences in total viral particles per culture. Total protein measurements made
following Ad-exposure (24h, 48h, 72h, 96h, 120h). Rearrangement of data from Figure 3-4.
Comparable levels of total viral particles are compared for the three different adenoviral
vectors. A) 120-140 virus particles (v.p.) per adenoviral construct. C) 240-350 v.p. per
adenoviral construct. Data represents mean ± SD of 2 biological replicates (2 technical
replicates per biological replicate). * P <0.01, significantly different from No Ad control.
3.3.3 Evidence of DHBV internalization and replication in DCPD-transfected rat
hepatocytes
The influence of DCPD expression levels on DHBV uptake was assessed by
immunofluorescence staining of permeabilized cells for DHBV preS envelope protein.
Approximately 72h following adenovirus exposure cells were incubated with DHBV for
24h, washed, fixed (2% PFA), and permeabilized (100% MeOH). Immmunofluorescence
staining for DHBV preS was followed by flow cytometry. As shown in Fig 3-6A, those
hepatocytes expressing more DCPD via adenovirus transfection demonstrated greater
DHBV binding as evidenced by detection of DHBV preS envelope protein. For increasing
Ad-eGFP-DCPD MOI the percentage of DHBV preS-positive cells appears to plateau
around -4.5% (Table 3.2), a value significantly smaller than the percentage of cells that
appear to express DCPD. Several factors may account for the relatively low percentage of
cells observed to express preS envelope protein. Several groups have determined that
DHBV internalization in PDHs occurs in <3h [182, 183]. Once internalized, preS protein
is unstable and is rapidly cleared by cellular proteases [184]. Production of viral proteins
begins -96h following DHBV uptake and therefore one would not expect to observe novel
preS production at this 48h timepoint [182]. Hence, the preS protein detected in cells at
48h following DHBV exposure reflects the amount remaining after 20-45h of proteolytic
digestion.
Western blot analysis of cells subjected to the same DHBV infection protocol as
those analyzed by flow cytometry also indicates that DHBV protein is being internalized as
evidenced by DHBV preS envelope protein (Fig 3-6b). These cultures were exposed to
Ad-eGFP-DCPD MOI= 10. Although flow cytometry measured relatively few cells
expressing DHBV preS at 48h following DHBV exposure the western blot analysis reveals
that preS expression was maintained for over 13 days following DHBV exposure. Such
maintenance is consistent with viral replication taking place within these cells. Western
blot analysis of supernatant samples collected from the same experiment demonstrate preS
envelope protein in the media of DCPD-transfected cultures which is consistent with viral
particles being secreted (Fig 3-6c). Equal amounts of total protein is loaded per lane.
Band intensity analysis indicate that 5 days after DHBV exposure there is -200% increase
in preS protein in the supernatant in comparison to preS levels present by day 1 post
DHBV exposure. This is consistent with other studies that report viral progeny in the
media of infected duck hepatocytes -4 days following DHBV infection [182]. 13-actin was
not detected in the blot (data not shown) confirming that the observed preS envelope
protein in the media was not associated with cells present in the media. It should be noted
that these blots are representative of several experiments.
There is also evidence of DHBV particles being internalized in the control
condition (i.e. Ad-eGFP) (Fig. 3-6c). However, it should be noted that unlike DCPD-
transfected hepatocytes, DHBV preS protein is being lost over the culture period in the
control condition. The absence of DHBV preS protein in the media samples confirms that
the viral uptake does not lead to any evidence of viral replication (Fig. 3-5d).
Recombinant adenovirus particles have been shown to mediate uptake of non-viral
macromolecules (e.g. proteins, dextrans, DNAs) possibly through macropinocytosis [185-
187]. However, this phenomenon was transient and occurred within minutes following
adenovirus exposure. In the present study DHBV was added to the media approximately
48h following adenovirus being washed out of the system which most likely excludes
adenovirus-mediated uptake.
DHBV infection on in vitro PDHs is an inefficient process. It has been
demonstrated that under synchronized virus adsorption with an inoculum enriched for
infectious particles as few as 10% of PDHs stained positive for DHBV core antigen by 7
days post-inoculation. DCPD-transfected PRHs in the present work were exposed to
asynchronous viral adsorption using an inoculum that was not enriched for infectious
particles. Therefore, -5% of the DCPD-transfected population staining positive for preS
protein is not necessarily low in comparison to the inefficient infection seen during in vitro
PDH infection.
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Figure 3-6. DHBV preS envelope protein demonstrates evidence of viral replication in
DCPD-transfected PRHs. A) Density plots of PRHs exposed to increasing Ad MOI
followed by DHBV exposure. Fixed and permeabilized samples represent 120h culture
period (48h post DHBV-exposure). For increasing DCPD+ cell population the
percentage of cells expressing DHBV preS plateaus at -5%. B) Representative western
blot of preS protein expression in DCPD-transfected PRHs (Ad MOI= 10). Maintenance
of preS protein is consistent with active viral replication. C) Representative western
blot demonstrates freely available preS protein in media of DCPD-transfected PRHs
which is consistent with virus being secreted into media.
No Ad
Ad-eGFP-DCPD M012
Ad-eGFP-DCPD M015
Ad-eGFP-DCPD MI010
Ad-eGFP-DCPD M0120
Ad-eGFP-DCPD M0150
Ad-eGFP M012
Ad-eGFP M015
Ad-eGFP MI010
Ad-eGFP M0120
Ad-eGFP M0150
preS+/GFP+ (120h)
% FACS (% of total pop.)
0.10
0.28
0.61
4.69
6.15
5.54
0.75
0.21
1.13
1.55
0.30
(0.04)
(0.04)
(0.19)
(1.18)
(1.73)
(3.18)
(0.21)
(0.07)
(0.66)
(2.78)
(1.23)
preS-/GFP+ (120h)
perm
% FAGS (% of total pop.)
0.60
8.20
24.00
46.70
66.50
67.60
2.91
11.00
31.30
65.10
90.50
(0.24)
(2.33)
(8.10)
(27.23)
(-100)
(-100)
(0.43)
(3.43)
(7.87)
(18.33)
(51.93)
Table 3-2. FACS Analysis of DCPD-transfected PRHs 48h following DHBV exposure
In addition to viral protein, DCPD-transfected cultures exposed to DHBV were also
analyzed for DHBV DNA. Southern blot analysis reveals evidence of DHBV DNA
intermediates in DCPD-transfected PRHs (Fig. 3-7). Among the many forms in which
DHBV DNA exists, single-stranded DHBV DNA (ssDNA) is not present in a mature
secreted particle. ssDNA appears during the viral life cycle when the viral pregenomic
RNA (pgRNA) is being converted into relaxed circular DNA (rcDNA). Its presence
indicates active viral replication taking place in these DCPD-transfected rat hepatocytes.
There are relatively small amounts of DHBV rcDNA and dslDNA present in the Ad-eGFP
control cultures. These DNA forms are found in the mature infectious DHBV particle. As
mentioned in the previous section the adenovirus could be mediating DHBV uptake in
these controls but the absence of ssDNA intermediates suggests that the virus is not
undergoing viral replication. This is a representative blot demonstrating the typical results
that are observed. It should be noted that this representative southern blot was not run with
equally loaded DNA in each well. Due to the loss of cells over the course of these
experiments, as discussed earlier, attempts to load equal DNA led to signals that were
lower than the detection sensitivity of southern blot analysis.
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no Ad Ad-eGFP Ad-eGFP-DCPD
1 5 9 13 1 5 9 131 5 9 13 days post-DHBV exposure
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* dslDNA
* ssDNA
Figure 3-7. Representative southern blot image of DCPD-transfected PRHs (Ad MOI= 10)
demonstrates presence of multiple DHBV DNA replicative intermediates. Lanes are not
equally loaded.
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3.3.4 DCPD expression in rat hepatocytes maintained in multi-well microreactor
Adenoviral-mediated transfer of DCPD initiated DHBV replication in freshly
isolated PRHs. This phenomenon was lost if PRHs were cultured for a few days prior to
DCPD transfection (data not shown). The loss is most likely attributed to the decrease in
liver-specific factors necessary for the initation of viral replication when primary
hepatocytes are cultured on collagen-coated polystyrene [146]. A three-dimensional
perfused culture system that recapitulates key aspects of the liver microenvironment has
been previously described [164]. Previous characterization has demonstrated that the 3-D
perfused culture system maintains a liver phenotype closer to that of native liver than other
standard culture systems (e.g. collagen-coated polystyrene, collagen gel sandwich) [9, 10].
To investigate the possibility of applying a similar infection strategy in this system
adenovirus was added directly to the media in the reservoir. Following a 24h incubation
the adenovirus was washed out. At different timepoints following Ad exposure the
scaffolds, containing the cells, were removed from the microreactor, fixed, permeabilized
and stained for DCPD expression. Confocal imaging reveals DCPD expression throughout
the tissue formed in the channels (Fig 3-8). Co-localization of the GFP and the AlexaFluor
568-conjugated secondary antibody to detect the DCPD reveals mainly cell surface
expression of the DCPD. As with the FACS analysis in Fig 3-3 there are also cells present
in the channel which are positive for the DCPD and negative for the GFP. These data
indicate that the PRHs maintained in the microreactor can be transfected with DCPD.
Differential DCPD expression throughout the tissue structures suggests differential Ad
exposure within the tissue.
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3.4 Discussion
Previous research has demonstrated that freshly isolated PRHs are capable of
producing infectious viral progeny upon transfection of the DHBV genome. DHBV was
able to cross the species barrier and effectively replicate using following the artificial
delivery of the viral genome to the host cell nucleus. In this study we have established that
PRHs are capable of supporting viral replication upon transfecton of DCPD, the known
internalization receptor for DHBV.
In this study the E1/E3-deleted recombinant Ad5 vectors carrying both DCPD and
GFP transgenes under separate CMV promoters were generated. Although GFP is
generally used as a marker for expression of both transgenes our analysis revealed the
presence of subpopulations that differentially express GFP and DCPD. Fluorescence
micrographs showed that the percentage of GFP-positive cells noticeably declined over 5
days following Ad exposure, DCPD expression was maintained for - 2 weeks via western
blot analysis. This differential expression could be due to an adenovirus-mediated
retention of the DCPD. FACS analysis revealed that the majority of DCPD was available
at the cell surface in the DCPD-transfected cultures. This is in contrast to other studies in
which DCPD is only transiently available at the cell surface. A 20-residue region within
the cytoplasmic tail of CPD binds Protein Phosphatase 2A (PP2A). It has been shown that
when the binding of PP2A to DCPD is inhibited or competed with via microinjection of
the CPD cytoplasmic tail the rate of movement of CPD from the cell surface to the TGN is
greatly slowed [188]. This suggests that PP2A plays an important role in the intracellular
trafficking of CPD. E1/E3-deleted Ad vectors still express low levels of wild-type gene
products that include E4 [189]. Studies have shown that the primary target of E4 ORF4 is
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PP2A [190]. It is possible that E4 ORF4 protein is competing with DCPD to bind PP2A
and effectively "trapping" the 180kDa DCPD at the cell surface.
The 2 separate DCPD proteins (180kDa and 170kDa) detected in DCPD-
tramsfected PRHs has been also been observed in primary duck hepatocytes in other
studies. While the 180kDa probably represents the full-length membrane-bound form the
170kDa protein could be a truncated soluble version as seen in other studies [138, 191].
Such smaller soluble versions have also been seen in bovine and rat tissues [176, 192].
Other groups have shown that following DCPD-transfection the resulting 170kDa protein
demonstrated similar DCPD enzymatic activity, activation, and pH optimum. However,
the 170kDa protein demonstrated a lack of reactivity to antiserum raised against the C-
terminal tail which suggested that it was missing a significant portion of the
transmembrane domain and cytoplasmic tail [176]. This truncated protein could be the
result of proteolysis or differential mRNA splicing.
Another interesting finding of this study is the increased cell death in control
cultures observed with increasing Ad MOI which was not observed in DCPD-transfected
cultures. This cytotoxicity could not be explained by the overall difference in total viral
particles present in the adenovirus stock preparations. This suggests that DCPD appears to
be protective against Ad-mediated apoptosis. CPDs cleave individual amino acids
(specifically Arg or Lys) from the COOH-terminal portion of peptides and proteins.
DCPD is primarily located in the TGN and is thought to function in protein processing
along the secretory pathway. Cell surface CPD has been shown to mediate nitric oxide
(NO) production, via inducible NO synthase (iNOS induction), in both isolated perfused
rat lungs and rat lung microvascular endothelial cells [193]. Cell-surface CPD was shown
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to cleave various substrates and release extracellular Arg, which upon cellular uptake,
triggered NO production through iNOS. As the present data shows the majority of DCPD
being expressed in the DCPD-transfected PRHs is available at the cell surface. Various
media components (e.g. albumin, EGF) could serve as substrates for cell surface DCPD.
NO has a complex biological role that can be either beneficial or detrimental to a
cell. iNOS mediated NO has been shown to protect against hepatic apoptotic cell death
seen in models of sepsis and hepatitis [194]. Factors that determine whether NO protects
or injures include the amount, duration, and source of NO production. Therefore, it is
possible that DCPD being expressed at the PRH-surface is mediating sufficient NO
production for a sufficient time period that is protecting against adenovirus-mediated
apoptosis.
Although flow cytometry data revealed a low percentage of cells staining for preS
envelope protein these cells are demonstrating active viral replication. The combined
maintenance of intracellular preS levels and the increase in extracellular preS protein
detected at 5days post DHBV exposure is consistent with the secretion of viral progeny
that occurs during natural infection. Viral replication in DCPD-transfected PRHs was also
substantiated by the appearance of DHBV ssDNA, a viral form that appears during viral
replication. Southern blot analysis used unequally loaded total DNA but it has been
previously establish in this study that there is cell loss over the culture period. Therefore,
it is not possible to extract conclusions about trends seen in ssDNA expression. Although
control cultures did demonstrate some evidence of DHBV binding the loss of preS
expression over time and the absence of extracellular preS levels is consistent with the
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viral protein being degraded. The minimal levels of rcDNA most likely represent the non-
specific binding of DHBV particles.
Recombinant adenovirus particles trigger receptor-mediated endocytosis
concomitant with macropinocytosis which is thought to mediate uptake of non-viral
macromolecules (e.g. proteins, dextrans, DNAs) available in the extracellular fluid [185-
187]. Macropinocytosis, a major endocytic pathway involved in non-specific bulk fluid
phase uptake, has been described in murine hepatocytes [195]. Recently, macropinocytosis
has been suggested as a possible pathway for uptake of Vesicular stomatitis virus/HCV
pseudotyped viruses in HepG2 cells. One possible scenario would be that in addition to
the control Ad vectors causing increased cell death it also triggers macropinocytosis such
that DHBV particles could gain non-specific entry. However, Ad-triggered
macropinocytosis is transient and occurred within minutes following adenovirus exposure
in previously published studies using HeLa cells [187]. In the present study DHBV was
added to the media approximately 48h following residual adenovirus being washed out of
the culture. Whether this phenomenon can still take place by this 48h timepoint is
unknown.
The strategy to render PRHs susceptible to DHBV infection was lost once freshly
isolated cells were cultured for a few days (data not shown). Such a loss is likely due to
the loss in expression of liver-specific factors necessary for the initiation of viral
replication when primary hepatocytes are cultured on collagen-coated polystyrene.
Confocal imaging demonstrates that DCPD expression via adenoviral delivery is feasible
in a more liver-like culture system. In standard culture the adenovirus has to diffuse
through the media to reach the layer of hepatocytes. It is assumed that with a well-mixed
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medium that the hepatocytes lining the dish have equal access to the adenovirus particles.
In multiwell culture diffusive and convective transport through the tissue in each channel
will affect the adenovirus exposure for hepatocytes such that the MOI seen by hepatocytes
at the fluid-tissue interfaces differs from the MOI experienced by hepatocytes located
adjacent to the channel wall. Such considerations represent a more physiological condition
in which cells with closer proximity to incoming blood experience greater access to
oxygen and nutrients than cells located closer to the exiting blood as in the metabolic
zonation of the hepatic acinus [33-35]. It was demonstrated in this study that PRHs
cultured in the multi-well microreactor can be transfected with DCPD. Differential DCPD
expression throughout the tissue does suggest differential exposure as well as differential
translational machinery.
DCPD-transfected PRHs do represent a novel system in which to study the early
steps of the DHBV life cycle. Viral markers indicate a relatively slow infection process
but similar inefficiency is seen during DHBV infection of in vitro cultures of PDHs. We
have also demonstrated that recombinant adenoviral vectors can mediate an alternative
mechanism by which DHBV can non-specifically penetrate primary rat hepatocytes
although it does not seem to result in active replication.
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Chapter 4.
Prolonged Susceptibility to DHBV Infection in Rat
Hepatocytes Maintained in a 3D Perfused Culture
System
4.1 Introduction
Human Hepatitis B Virus (HBV) is the prototype member of the family
Hepadnaviridae that consists of enveloped, partially double-stranded DNA viruses that
specifically target cells in the liver for viral replication. Although a vaccine has been
available for more than 20 years chronic hepatitis B afflicts -5% of the world's population
(350 - 400 million) [11]. It is estimated that 500,000 to 1.2 million people die each year
from HBV-attributable cases of chronic hepatitis, cirrhosis, and hepatocellular carcinoma
[12, 13].
Currently available therapeutics include interferon alpha (IFNa). This naturally
occurring cytokine has a dual mode of action; the first being the inhibition of viral
replication and the second being the enhancement of the immunological response of the
host against the virus. The disadvantages associated with IFNa include a limited efficacy
rate, undesirable side effects, and an inconvenient dosing regimen (3 injections per week).
Studies have shown that the addition of a polyethylene glycol (PEG) molecule to IFNa
significantly increases the half-life and leads to more sustained activity[21, 22]. Other
therapeutics include nucleoside analogues (e.g. lamivudine) which are synthetic molecules
that, following conversion into nucleoside triphosphate equivalents, compete with natural
nucleoside triphosphates for incorporation into viral DNA by the viral DNA polymerase.
Since these analogues lack a bond site necessary to link it to an adjacent nucleoside their
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incorporation effectively terminates the elongation of nascent viral DNA chains and
therefore inhibits viral replication. Lamivudine which is administered orally has minimal
side effects. However, it does display a modest efficacy rate of 20-30% following a 12
month dosing regimen [23]. Following therapy termination most patients experience a
relapse evidenced by the detection of viral DNA and HBeAg in the serum [24].
Continuous lamivudine treatment is necessary for a sustained therapeutic effect. This is a
major drawback when combined with the observation that lamivudine-resistant HBV
species emerge during long-term treatment [23, 24]. These therapeutics interfere with viral
replication but it is prudent to develop novel therapeutics which target earlier events in the
viral life cycle (i.e. viral attachment, viral uptake, fusion, delivery to the host cell nucleus).
Combined antiviral therapies that target both early and late viral life cycle events may be
more effective in suppressing viral replication and preventing relapses observed when
current drug therapies are discontinued [196, 197].
Future antiviral drug therapy is dependent on the development of better cell culture
systems. To date, no successful in vitro system has been developed for chronic HBV
infection wherein the entire viral life cycle can be studied. The use of primary human and
primate hepatocytes is restricted by multiple experimental limitations including a rapid loss
of susceptibility to infection in culture, lot-to-lot variability in susceptibility to infection,
and the necessity of treatment with chemical agents such as DMSO for reproducible
infection [107, 108, 120]. Permissive cell lines (e.g. HepG2, Huh7) are capable of
supporting viral replication upon transfection with the viral genome. HepG2.2.15, a
subline of HepG2, is stably transfected with multiple copies of the HBV genome [121].
HepG2.2.15 cells express all viral RNAs and proteins, produce viral genomes, and secrete
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virus-like particles. These cell lines have shed greater light on the later events in the viral
life cycle (i.e. transcription, encapsidation reverse transcription, virion assembly, export).
However, there is less understanding of the early stages that include virus attachment,
internalization, uncoating, genome repair, and nuclear transport. These cell lines do not
mimic natural infection which limits their usefulness. An in vitro system that will allow us
to target other aspects of the viral life cycle is needed.
Recently, a cell line known as HepaRG was shown to be susceptible to infection
under certain conditions. In the presence of PEG, DMSO, and/or hydrocortisone HepaRG
cells exhibit hepatocyte-like morphology, express liver-specific functions (e.g. albumin,
aldolase B, CYP3A4), and demonstrate phase I and phase II drug metabolism enzyme
activity in the range of normal human hepatocytes [122]. DMSO and hydrocortisone are
known inducers of cell differentiation although the underlying mechanism is not known.
Hepadnaviruses are subdivided into two categories based on sequence homology;
orthohepadnaviruses which infect mammals and avihepadnaviruses which infect birds.
Duck HBV (DHBV) was the first avihepadnavirus detected while others have been
isolated more recently from grey herons, snow geese, white storks, and cranes.
Avihepadnaviruses share little sequence homology with orthohepadnaviruses (-40%).
DHBV expresses two major envelope proteins (instead of three) (Section 1.6.2). However,
similar genome organization, virus structure, and replication characteristics among
hepadnaviruses warrant the study of hepadnaviruses found in other species. Many of the
principles of hepadnavirus life cycle were elucidated by studying duck hepatitis B virus
(DHBV) as a model for HBV. Some of these principles include the replication by reverse
transcriptase [125], cccDNA formation [126], and host-range determinants [127-129].
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However, reproducible in vitro infection of primary duck hepatocytes requires culture
conditions that incorporate 1.5-2% DMSO whose mechanism of action is unknown [130,
131]. Even with such artificial additives the kinetics of in vitro infection are slow and
inefficient when compared to in vivo infection of neonatal ducklings [132].
Our group has developed an in vitro system that recreates a perfused liver capillary
bed structure. This perfused three-dimensional culture system recapitulates key aspects of
the liver microenvironment in order to maintain a well-differentiated liver phenotype as
evidenced by multiple criteria (e.g. biochemical production, tissue morphology, liver-
enriched mRNA expression, and drug metabolism) [9, 10]. Using a novel method to
render PRHs susceptible to DHBV this study demonstrates that PRHs cultured in this
microreactor remain susceptible to DHBV infection at longer timepoints in culture than in
standard tissue culture.
4.2 Materials & Methods
4.2.1 Primary rat hepatocyte isolation and culture
Primary liver cells were isolated from male Fischer rats (150 - 230g) using a
modified version of Seglen's two-step collagenase perfusion procedure [164] as previously
described [165]. Tissue dissociation was accomplished using Liberase Blendzyme 3
(Roche). Final cell viability was in the range of 89-94 % based on trypan blue exclusion.
The final cell pellet (-95% hepatocytes) was re-suspended in supplemented DMEM
(GIBCO) that includes 0.03g/L proline, 0. 10g/L ornithine, 0.305g/L niacinimide, 2.0g/L
glucose, 2.0g/L galactose, 2.0g/L bovine serum albumin, 0.05mg/mL gentamycin, 5mg/L
insulin, 5mg/L transferrin, 5ug/L sodium selenite, 20ng/mL epidermal growth factor, 1mM
L-glutamine, 0. luM dexamethasone, and trace metals (5.44mg/mL ZnC12, 7.5mg/mL
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ZnSO 4-7H20, 2.0mg/mL CuSO4-5H20, 2.5mg/mL MnSO 4) collectively referred to as
Hepatocyte Growth Media (HGM) [166]. Resuspended hepatocytes were plated on
polystyrene plates coated with collagen type I (30 gtg/mL) (BD Biosciences) at a plating
density of 50,000 cells/cm2. Cultures were maintained at 370 C and 5% CO2 with media
changes every 48h.
4.2.2 Preparation of spheroidal cell aggregates in spinner flasks
Spheroidal cell aggregates were formed in suspension as previously described [9,
164]. Briefly, freshly isolated hepatocytes were added to spinner flasks (BellCo, USA) at
3x10 5 hepatocytes/mL HGM and cultured on a spinner table at 84rpm (37°C and 8.5% CO2
with humidity) to induce spheroid formation. Following a 24hr culture period, 50- to 300-
[im spheroids were collected by filtering through appropriately sized nylon meshes
(SEFAR America, Kansas City, MO), pelleting (50xg, 3min), and resuspending in HGM.
4.2.3 Giant microreactor culture
The giant microrreactor is a multilayered structure whose design and assembly
have been described elsewhere [7]. Briefly, the main portion of the microreactor is a
polycarbonate scaffold (-230p.m thick) that contains a regular array of channels into which
cells are seeded. The scaffold is positioned on a microporous filter that is mechanically
supported by a second scaffold. Cooled drilling methods were employed to make the array
of evenly spaced channels (1000 total channels), each with a 300[tm diameter. The
primary scaffold channels are coated with collagen type I (30Rg/mL) to allow for cellular
attachment. The fully assembled microreactor was primed with HGM to passivate the
reactor, connector, and tubing surfaces, and to remove air bubbles from the flow paths.
Immediately prior to seeding, fresh HGM was added to the media reservoir. Seeding was
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accomplished by removing the top polycarbonate window and pipetting -I mL of
spheroidal cell aggregate suspension onto the polycarbonate scaffold. A downward
crossflow was maintained during seeding in order to pull the spheroidal aggregates into the
channels. The microreactor was also gently rocked back and forth to ensure even seeding
across all the channels. Excess spheroids were carefully aspirated off the scaffold. After
replacing the top window the peristaltic pumps were used to set flow rates which were
chosen based mainly on physiological shear stress conditions [9, 164]. During the first 24h
the media perfuses the channels in a downward direction to pull the cells into the channels.
After 24h the media crossflow is reversed in order to eliminate cellular debris from the
channels and fresh media is added to the reservoir. Microreactors were maintained at
370 C, 8.5% CO2 with media changes every 72h.
4.2.4 Multi-well microreactor culture
A B
Controller , Bloreactor Plate
Reactor Well & Surface Pneumatic Reservoir
Scaffold Assembly Channel Pump Well
pneumat reactor urat
lnes
C
scaffold tissue filter filter
unit SUDDOrt
flow
Figure 4-1. Diagram of multi-well microreactor. A) Image of microreactor connected to
controller device for pneumatic pumps. B) Image of individual reactor unit consisting of
media reservoir and a reactor well containing the scaffold assembly which is connected by a
surface channel and a pneumatic pump. C) Illustration of scaffold assembly with tissue in
channels.
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A schematic of the microreactor and fluidic circuit is shown in Figure 4-1. The
microreactor is a multilayered structure whose design and assembly have been previously
described [170]. Briefly, there are 12 reactor units on a single fluidic plate. Each
microreactor unit consists of a scaffold assembly and a media reservoir. The
polycarbonate scaffold has an array of 800 circular channels (diameter = 300[im, depth =
230tm). Cells in the scaffold channels are continuously perfused with culture media from
the reservoir via a pneumatic pump which is then recirculated across a surface channel
back to the reservoir. Each reactor unit is fluidically isolated but all pumps are
simultaneously driven by pneumatic control lines connected to sources of positive and
negative air pressure. Physiological rates of media perfusion are achieved by controlling
the frequency of the pulses of air pressure. Primary scaffold channels are coated with
collagen type I (30tg/mL) to allow for cellular attachment. Prior to seeding, the
microreactor system is primed with HGM in order to passivate the surfaces and remove
any air bubbles in the fluidics. Primary cells isolated from the rat perfusion are pipetted
directly into the channels of the scaffold and adhere to the collagen coating the channel
walls. During the first 8h the media perfuses the channels in a downward direction in
order to pull the cells into the channels. To eliminate any residual cell debris that might
clog the filter the media flow is reversed (lower chamber to upper chamber) after 8h and
fresh media is added to the reservoir. Microreactors were maintained at 37oC and 5% CO2
with daily media changes.
4.2.5 Generation of recombinant adenovirus vectors
The adenovirus constructs were generated using the AdEasy Vector System as
previously described [146]. Briefly, a shuttle vector containing the gene of interest
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(DCPD) and an adenovirus backbone plasmid that includes the Ad5 genome with both El
and E3 genes deleted were co-transformed into an E. coli strain (BJ5183). The highly
efficient homologous recombination machinery within the bacteria produce recombinant
adenovirus constructs containing the gene of interest. These constructs are linearized and
transfected into the 293 packaging cell line which constitutively express El gene products,
necessary for propagation of all recombinant adenoviruses. Successful viral production is
monitored via the GFP reporter gene which is also incorporated into the adenovirus
backbone plasmid. Further tests were done to confirm that there were no replication-
competent adenovirus constructs present in the final preparations. The final recombinant
adenovirus containing the DCPD gene is designated Ad-eGFP-DCPD. This vector was
kindly provided by the Wands laboratory at Brown University. Further amplification and
purification was performed by Puresyn, Inc.
4.2.6 DHBV-positive serum isolation
Mammoth White Pekin ducklings were obtained from a commercial supplier
(Ridgway Hatchery), housed at the Liver Research Center at Brown University, and given
ad libitum access to food and water. Three-day old ducklings were injected in a foot vein
with 200uL of highly viremic duck serum. Five days later the duck was sacrificed by
pentobarbital overdose (Abbott Laboratories) and the total blood volume was collected via
cardiac puncture. Total blood was kept at room temperature for -6hrs and then spun (3000
rpm) for 5 min. The serum was collected and tested for DHBV particles via dot blot
analysis. Briefly, total DNA was isolated using QIAamp DNA MicroKit (Qiagen), boiled
at 100C for 10 min and placed immediately on ice. DNA was spotted onto nylon
membrane (Schleicher & Schuell) and fixed using UV exposure. A 32P-radiolabeled
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DHBV DNA probe was added overnight (45C). Following multiple washes, the blot was
exposed to a phosphor screen that was developed on a Cyclone Imaging Station (Packard
Bioscience).
4.2.7 DHBV infection
4.2.7.1 Standard 2D culture
Approximately 6h after plating, cultures were exposed to adenovirus vectors
diluted in HGM to achieve the proper multiplicity of infection (MOI). Cells were cultured
with the adenovirus for -24h at 37C prior to being removed with multiple washes of
Phosphate Buffered Saline (PBS). DHBV-positive duck serum was diluted (1/5) in HGM
and added to the cultures for 24h incubation at 370 C. The diluted serum contained - 4x10 8
virus genome equivalents (vge) as determined by PCR analysis. Non-adsorbed virus
particles in the culture were removed with multiple PBS washes. Cells were maintained at
370 C with media changes every 48h.
4.2.7.2 Multi-well microreactor
Approximately 6h following seeding single cells into the multi-well cultures were
exposed to adenovirus vectors diluted in HGM to achieve the proper multiplicity of
infection (MOI). Cells were cultured with the adenovirus for -24h at 37C followed by
multiple HGM washes to remove excess vectors. DHBV-positive duck serum was diluted
(1/5) in HGM and added to the cultures for 24h incubation at 370 C. The diluted serum
contained - 4x10 8 virus genome equivalents (vge)/mL as determined by PCR analysis.
Excess virus particles in the culture were removed with multiple PBS washes. Cells were
maintained at 370C with media changes every 24h.
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4.2.8 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and
Western blot analysis
Cell samples were lysed with 100uL RIPA buffer on ice for 20 minutes and total
protein was determined by BCA protein assay (Pierce). SDS-PAGE was done using 7.5 or
12% polyacrylamide gels (BioRad). Prior to loading the gel, samples were adjusted so that
equal amounts of total protein were loaded onto the gel. Following electrophoresis,
proteins were transferred to a polyvinylidene difluoride (PVDF) membrane (BioRad,
USA). The PVDF membrane was probed with primary antibodies that included:
polyclonal rabbit anti-DGD (1:20000 dilution), polyclonal rabbit anti-actin (1:5000
dilution; Santa Cruz) and polyclonal goat anti-HNF4a (1:5000 dilution) (Santa Cruz).
Primary antibodies were detected with either goat anti-rabbit HRP-conjugated secondary
antibody (1:5000 - 1:10000 dilution) (Jackson Immunoresearch) or rannit anti-goat HRP-
conjugated secondary (1:500 - 1:1000 dilution) (Santa Cruz). Detection and quantification
were done using enhanced chemiluminescence (ECL) (Amersham, USA) and a Kodak
Image Station (Eastman Kodak).
4.2.9 Isolation and detection of DHBV DNA in primary rat hepatocytes via
quantitative real-time PCR analysis
Frozen cell samples were thawed to room temperature and total DNA was extracted
with the DNeasy Tissue Kit (Qiagen). Using a strategy adapted from Kock & Schlicht
[198] we developed a real-time PCR assay in which a primer/probe set is targeted for a
region in the DHBV genome that is common to all viral DNA forms (Table 4-1). For
dslDNA, the region targeted by the primer/probe set is unaffected by the linear nature of
the viral DNA. It should be noted that the ssDNA includes the complete (-) strand and
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would be detected by the probe and the forward primer of Set A. However, since the (+)
strand is absent, ssDNA would not be amplified during the PCR and therefore would not
contribute significantly to the fluorescent signal. The second primer probe set (Table 4-1)
is designed to converge upon the gap region in the (-) strand of the DHBV genome. This
gap is present in rcDNA but not in cccDNA. Again, ssDNA would not contribute
significantly to the signal for the reason mentioned earlier. dslDNA is also not detected by
the second primer/probe set because the gap region is effectively infinite due to the
linearity of the viral DNA form. Therefore the second primer/probe set is selective for
cccDNA.
Standard curves were established by isolating total DNA from DHBV+ Pekin duck
liver (Qiagen DNeasy Tissue Kit and QIAamp DNA Micro Kit). Almost full-genome
length DHBV DNA fragments were amplified via PCR consisting of thermostable DNA
polymerases with proofreading activity and DHBV-specific primers (Expand High Fidelity
PCR System, Roche). The amplified product was run on 1% agarose gel and the DHBV
DNA band (-3kb) was excised and purified (QIAquick Spin Kit, Qiagen). This purified
DHBV DNA was quantified spectrophotometrically (Nanodrop) and represents total
DHBV DNA. In the literature it has been found that cccDNA represents -2% of total
intracellular viral DNA [199]. Using these data, real-time PCR assays using total DHBV
DNA-specific and cccDNA-specific primer/probe sets (Table 4-1) were run using serial
dilutions of DHBV DNA.
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4.2.10 Fluorescence analysis
Cultures maintained on collagen-coated polystyrene dishes were imaged using a
Zeiss Axiovert 100 microscope. GFP expression was imaged using a fluorescein
isothiocyanate (FITC) filter.
4.2.11 Statistical Analysis
Statistical significance of results was analysed using GraphPad Prism Version 4.0
for Windows (GraphPad Software, San Diego, CA). Student's t-test was used to compare
differences between two groups. Results were considered significant when probability
values were <0.10.
Almost tull-length
DHBV genome
primers FW 33 5'-CTACATTGCTGTTGTCGTGTGT-3'
REV2932 5'-AAGGG I I TGTGUUCTGGAT-3'
lotal UHISV UNA-
specific (rcDNA,
dslDNA,cccDNA) FW 1374 5'-GGCTAGATTGGTGGTGGATT-3'
HEV1 520 5'-AAAGCUT GAGATIAGGI CCAAAG-3'
PROBE1426 5'[FAM]-CGCTTTCCAAGATACTGGAGCCCA-[TAMRA]3'
DHB3V cccDNA-
specific FW 125 5'-TCCTGATTGGACGGCTTT-3'
REV272 5'-GTCACACACGACAACAGCAA-3'
PROBE216 5'[FAM]-CCTTCGGAGCTGCTTGCCAAG-[TAMRA]3'
GAPDH-specific FW2242 5'-TGGGATAGCCAGTGCTCTTA-3'
REV2322 5'-AUAGGAGA IGGTTIGGAACT-3'
PROBE2267 5'[FAM]-TGAGCCATCATCATCTCCGCTG-[TAM RA]3'
Table 4-1. Primer/probe sets designed to amplify different DHBV DNA forms.
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43 Results
4.3.1 Maintenance offactors necessary for DHBV replication
It has been previously demonstrated that duck glycine decarboxylase (DGD) is a
necessary protein that mediates a postbinding step in DHBV replication [146]. These
previous studies revealed that diminished primary duck hepatocyte (PDH) susceptibility to
DHBV infection correlates with declined DGD protein expression. Sprinzl et. al. [175]
demonstrate that upon transfection with the DHBV genome immediately following plating,
primary rat hepatocytes produce both cccDNA and infectious DHBV progeny. This
evidence indicates that by circumventing the natural process the DHBV employs to
penetrate the host cell, the rat homolog of proteins such as glycine decarboxylase are
sufficient to establish productive replication.
Following rat liver perfusion, PRHs were cultured in both the collagen-coated
microreactor and standard collagen-coated monolayer on polystyrene. At multiple
timepoints during culture cell samples were lysed in RIPA buffer and analyzed for rat
glycine decarboxylase (GD). Western blot analysis indicates GD is better maintained in
microreactor culture than standard monolayer culture (Fig. 4-2). Using band intensity
analysis the GD expression at multiple timepoints was compared to GD expression in
PRHs immediately following the perfusion. In microreactor culture there is a -2-fold
increase in GD expression after 1 day in culture. By day 7 there is -50% GD being
expressed relative to that found in PRHs immediately following perfusion. Over the next 2
weeks the GD expression decreases such that there is -25% retention of rGD after 21 days
in microreactor culture. In contrast, PRHs in monolayer culture demonstrated -90%
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retention of GD expression following 1 day in culture. By day 7 GD expression is -25%.
There was no GD expression seen by day 14 in monolayer culture.
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Figure 4-2. Glycine decarboylase expression over 21 days in culture. At indicated
timepoints cells were lysed and SDS-PAGE analysis was run using equal amounts of total
protein for all timepoints. Bar graph data represents band pixel intensity at indicated
timepoint relative to band pixel intensity measured in cells immediately following rat liver
perfusion. Mean GD expression is significantly different between the monolayer and
microreactor cultures (null hypothesis rejected for p<0. 10.).
Glycine decarboxylase belongs to a multienzyme complex known as the glycine cleavage
complex that is the primary pathway for glycine catabolism. While this complex is located
in the mitochondria, GD has been shown to be available on the cell surface in PDHs as
well as in stably transfected 293 cells and transiently transfected LMH and Bosc cells
[145].
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Tang and McLachlan [148] have also indentified liver-enriched transcription
factors that support DHBV replication in nonhepatic cells. Upon transfection of a
replication-competent DHBV genome and various liver-enriched transcription factors it
was shown that Hepatocyte Nuclear Factor 3 (HNF3) and HNF4 support replication of
DHBV DNA intermediates. Previous studies in our group have demonstrated that the
microreactor displays better maintenance of various liver enriched transcription factor
mRNAs including HNF3a and HNF4a mRNA following 7 days in culture in comparison
to standard 2D cultures (Fig 4-3a). Western blot analysis demonstrates that this better
maintenance extends to the protein level (Fig 4-3b).
The representative blot in Figure 4-3c shows that the microreactor demonstrates
better HNF4a protein expression at 21 days in culture in comparison to standard
monolayer culture.
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Figure 4-3. Liver-enriched mRNA and protein expression over time in culture. A)
Total mRNA isolated on day 7 of culture using TRIzol. Baseline in the plot represents
mRNA detected in liver slices taken directly after rat sacrifice. B) SDS-PAGE
analysis of HNF4a expressed by day 7 in culture. IsoHeps: hepatocytes in suspension
following rat perfusion, 3D: liver microreactor, 2D: collagen gel sandwich culture. A)
and B) adapted from [10]. C) SDS-PAGE analysis of HNF4a expression in
microreactor (rxr) and adsorbed collagen monolayer (mono) culture.
4.3.2 Early and late DCPD-transfection in monolayer culture
As discussed in the previous chapter DCPD expression via adenoviral transfection
can be increased using increasing Ad MOI but this also results in greater cell death. Ad
MOI =10 was used in the following experiments because it achieves a sufficient
transfection efficiency (assessed visually under microscope) while causing only moderate
cell death. Figure 4-4a shows representative images of 72h cultures of cells transfected
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-6h after plating. These images confirm that there is some cell death but a decent
percentage of these cells are transfected as evidenced by GFP expression. In the previous
chapter total protein analysis revealed that this cell death was not significantly different
than that observed in No Ad control cultures.
In Figure 4-4b cultures were maintained for 14 days prior to exposure to Ad MOI =
10. Total cell number present at these longer time points tend to be less than that
originally seeded. In order to ensure that the Ad MOI = 10 at the later timepoint it was
necessary to maintain parallel cultures. On the day that the adenovirus was added total
DNA was extracted from the parallel cultures and real-time PCR using primers specific for
GAPDH DNA was used to determine total cell number (Table 4-1). A standard curve was
previously prepared using known cell concentrations taken directly from multiple rat
perfusions.
Phase contrast images demonstrate significant morphological changes. The
hepatocytes tend to clump into nodes while fibroblast-like cells appear in between the
nodes. The fluorescent images demonstrate that fewer GFP-positive cells are present.
This is either due to an overall loss in hepatocytes or a loss in factors necessary for the
recombinant adenovirus to successfully deliver the GFP and DCPD transgenes. Previous
studies have shown that the Coxsackie- and Adenovirus (CAR) receptor mRNA is down-
regulated over time in collagen gel sandwich culture (Section 2.7.2, Fig. 2-10). Assuming
similar behavior in the adsorbed collagen monolayer culture employed here the decrease in
GFP-positive cells could be a result of decreased adenoviral uptake.
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Figure 4-4. Early and late DCPD-transfection in monolayer culture. PRH cultures plated
on collagen-coated polystyrene were exposed to adenovirus (Ad MOI=10) either A) -6h
following plating or B) after 2 weeks in culture.
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4.3.3 Early and late DCPD-transfection in microreactor culture
Originally, microreactor culture incorporated seeding of spheroidal cell aggregates
[164]. To maintain a similar timecourse of DHBV exposure it was necessary to add the
adenovirus to the spinner flask as the PRHs were forming spheroids. Qualitatively the
majority of the non-filtered spheroids appear GFP-positive after 24h in culture (Fig 4-5a).
Trypan blue exclusion confirms good cell viability in these spheroids. One day following
seeding into the microreactor demonstrates tissue-like structures present (Fig 4-5b). The
GFP expression (-48h following Ad exposure) has also increased as would be expected
based on monolayer studies.
More recently our group has investigated seeding microreactor cultures with single
cells taken immediately from the perfusion. Approximately 6h following microreactor
seeding the adenovirus is added to the microreactor reservoir. Images taken 24h later
indicate GFP-positive tissue structures forming (Fig. 4-6a). Cells maintained for longer
time periods were also exposed to adenovirus (Fig. 4-6b). Total cell number present at
these longer time points tend to be less than that originally seeded. Similar to the
monolayer situation described in the previous section, parallel cultures were mainained.
On the day that the adenovirus was added total DNA was extracted from the parallel
cultures and real-time PCR using primers specific for GAPDH DNA was used to
determine total cell number (Table 4-1). A standard curve was previously prepared using
known cell concentrations taken directly from multiple rat perfusions.
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4.3.4 Development of real-time PCR assay to quantify total DHBV DNA and cccDNA
A real-time PCR method was developed in order to quantitatively measure both
total DHBV DNA and particularly the cccDNA form (Fig. 4-7a). Using a strategy adapted
from Kock and Schlicht [198] primers and a probe were developed using Primer3 that
targets a region of the DHBV genome that is common to all viral DNA forms (Table 4-1).
For dslDNA, the region targeted by the totalDNA primer/probe set is unaffected by the
linear nature of the viral DNA. It should be noted that the ssDNA includes the complete
(-) strand and would be detected by the probe and the forward primer of the totalDNA
primer set. However, since the (+) strand is absent, ssDNA would not be amplified during
the PCR and therefore would not contribute significantly to the fluorescent signal. The
second primer probe set (Table 4-1) is designed to converge upon the gap region in the (-)
strand of the DHBV genome. This gap is present in rcDNA but not in cccDNA. Again,
ssDNA would not contribute significantly to the signal for the reason mentioned earlier.
dslDNA is also not detected by Primer/Probe Set B because the gap region is effectively
infinite due to the linearity of the viral DNA form. Therefore cccDNA primer/probe set is
selective for cccDNA. For DNA isolated from DHBV-infected duck livers the
primer/probe sets amplify products above the threshold at separate cycles (Fig. 4-7b). For
DNA isolated from uninfected duck livers the cccDNA primer/probe set amplifies nothing
over 45 cycles. The totalDHBV probe set does seem to non-specifically amplify a product
that reaches the threshold of detection at Ct -40 (Fig. 4-7b). This late amplification is
considered non-specific since these ducks were identified as being uninfected.
For total DHBV DNA the standard curve is linear over 9 orders of magnitude and
for the cccDNA the standard curve is linear over three orders of magnitude (Fig. 4-8). The
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lower limit of detection for this analysis is 0.67 viral genome equivalents (vge) for total
DHBV DNA and 1.3x104 vge for cccDNA. Using this real-time PCR assay the viral load
of the DHBV+ duck serum was determined to be -3.6x109 vge/mL which is consistent
with the literature for congenitally-infected Pekin ducks.
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Figure 4-7. Development of real-timer PCR assay for DHBV DNA quantification. A)
Illustration of DHBV rcDNA and cccDNA viral forms. Two primer/probe sets target
different regions (one region that is common to both viral DNA forms and another region that
is specific for cccDNA B) Total DNA isolated from both DHBV+ and DHBV- duck liver
and subject to real-time PCR analysis using both primer/probe sets.
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Figure 4-8. Real-time PCR primers/probe specific for either total DHBV DNA or DHBV
cccDNA. Serial dilutions of purified DHBV DNA were analyzed with either the total DNA-
specific primer/probe set or the cccDNA-specific primer/probe set. The total DHBV DNA
standard curve is linear over 9 orders of magnitude. The DHBV cccDNA standard curve is
linear over 3 orders of magnitude.
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4.3.5 DCPD protects against Ad-mediated cytotoxicity in microreactor culture
The Ad-mediated cytotoxicity that has been observed in freshly isolated PRH in
standard monolayer culture is also seen in microreactor culture. Ad control vectors (Ad-e
and Ad-eGFP) were incubated with either freshly isolated PRHs or PRHs that had been
maintained in culture for 2 weeks. Using measurement of total protein as an indicator of
cell number it is evident that increased cell loss occurs when freshly-isolated hepatocytes
are exposed to the control Ad vectors (Figure 4-9a). In contrast, DCPD-transfected
cultures demonstrate no significant cell loss compared to the control No Ad condition
(Figure 4-9b). Ad-mediated cytotoxicity is not observed in PRHs that are maintained in
culture for 2 weeks prior to being exposed to the adenovirus in monolayer culture.
Decreased cytotoxicity is observed in microreactor cultures but DCPD still appears to have
a protective effect in cultures maintained for 2 weeks prior to adenovirus exposure. As
discussed in the previous chapter adenoviral uptake occurs through receptor-mediated
endocytosis. The decreased cytoxicity could be due to a loss of necessary factors for either
Ad-specific uptake (e.g. Coxsackie- and Adenovirus Receptor) or hepatocyte-specific
replication machinery. Previous characterization in the lab has shown that the in
comparison to in vivo liver, CAR mRNA is down-regulated 7-fold in collagen gel
sandwich but only 2-fold in microreactor culture [7].
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Figure 4-9. Total cell number in monolayer and microreactor culture was
determined by measurement of total GAPDH DNA using real-time PCR analsysis.
A) DCPD protects against Ad-mediated toxicity at early timepoints in monolayer
culture. B) DCPD protects against Ad-mediated toxicity at both early and late
timepoints in microreactor cultures. N=1 biological replicate.
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4.3.6 DHBV DNA evidence in DCPD-transfected PRHs
In monolayer culture DCPD-transfected PRHs demonstrate a significant loss in
intracellular DHBV DNA levels (75%) when transfected at late timepoints (Fig. 4-10a).
The experimental timecourse is shown in Table 4.2. Real-time PCR analysis using
cccDNA specific primers demonstrates that the majority of the DNA present is in cccDNA
form (Fig. 4-10b). This loss of susceptibility to DHBV infection correlates with the loss of
factors that are necessary for DHBV replication shown earlier (Fig. 4-2 and Fig. 4-3)
Evidence of DHBV DNA in control Ad vectors is not significantly greater than the No Ad
control condition.
DCPD-transfected microreactor cultures demonstrate increased DHBV DNA levels
in comparison to monolayer culture (Figure 4-1 la). Real-time PCR analysis using
cccDNA-specific primers confirms that the majority of this DNA is in cccDNA form (Fig.
4-1 lb). The significant 3-fold increase in intracellular DNA in PRHs transfected after 2
weeks is surprising given that various factors necessary for DHBV infection (e.g. GD,
HNF4a) are down-regulated by this timepoint. It should be noted that this data represents
one biological replicate (2 technical replicates). Microreactor culture demonstrates well-
to-well variability that is most likely user-related (data not shown). It is possible that the
actual cell number used to determine the amount of adenovirus to add to the culture could
have been greater than the actual cell number present in the wells for the given
experimental condition. Further study is needed in order to determine whether this
phenomenon is typical.
Ad control vectors demonstrate significantly higher DHBV DNA levels than the
No Ad condition and the real-time PCR confirms that there is cccDNA present. As
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discussed in previous chapter (Section 3.4) it appears that Ad vectors are capable of
mediating some DHBV uptake although the precise mechanism is unknown.
It should be noted that the DCPD-transfected PRHs in microreactor cultures
demonstrate -10-80 DHBV cccDNA copies/cell while the monolayer cultures demonstrate
-0.1-10 DHBV cccDNA copies/cell. Persistent DHBV infection of the hepatocyte is
characterized by the presence of cccDNA. In natural DHBV infection process rcDNA is
delivered to the host cell nucleus where it is converted into episomal cccDNA. This viral
DNA serves as the template for all viral mRNA s that are translated and assembled into
viral progeny. Early during the infection cycle the DNA within nascent viral capsids is re-
imported into the nucleus which results in amplification of cccDNA and increased viral
replication. Late during infection the newly forming viral capsids are redirected to the
secretory pathway by the large envelop protein. This eventually leads to the secretion of
enveloped viral particles. Different groups report that infected primary duck hepatocytes
express 10 - 100 copies of cccDNA [126]. The greater pool size of cccDNA measured in
the DCPD-transfected microreactor cultures could translate into greater viral replication.
Further studies are warranted in which infected cultures are assayed for markers of viral
replication at multiple timepoints following DHBV exposure.
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Figure 4-10. DCPD-transfected PRHs demonstrate decreasing susceptibility
following extended culture (2weeks) in monolayer. A) Real-time PCR analysis
using total DHBV DNA-specific probe/primers. B) Real-time PCR analysis using
DHBV cccDNA specific probe/primers.
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Figure 4-11. DCPD-transfected PRHs demonstrate increased susceptibility
following extended culture (2weeks) in microreactor. A) Real-time PCR
analysis using total DHBV DNA-specific probe/primers. B) Real-time PCR
analysis using DHBV cccDNA specific probe/primers.
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4.4 Discussion
Previous studies (Chapter 3) investigated the ability of PRHs to support DHBV
infection when transfected with DCPD, the internalization receptor for DHBV, soon after
plating. Replicative intermediates (i.e. ssDNA) indicated that DCPD-transfected cells are
capable of productive DHBV infection. In this study we attempted to investigate the
ability of DCPD-transfected PRHs maintained in a 3D perfused culture system to support
DHBV infection at longer timepoints. Using various assays (e.g biochemical production,
tissue morphology, mRNA transcriptional profile, and enzyme activity) the microreactor
has been shown to maintain a more liver-like phenotype than conventional tissue culture
systems (i.e. collagen-coated monolayer, collagen gel sandwich) [9, 10].
Western blot analysis demonstrated that PRHs cultured in the microreactor
maintain more of the necessary factors for DHBV replication than PRHs cultured on
collagen-coated polystyrene. These factors include GD which mediates a postbinding step
during DHBV infection. The loss of DGD in primary duck hepatocyte cultures correlates
with the loss of susceptibility to DHBV infection [146]. After 3 weeks in culture PRHs in
the microreactor retain greater GD expression than monolayer cultures. Among the liver-
enriched transcription factors HNF4 is known to support DHBV replication [148]. HNF4a
is considered to be a master transcription factor due to its ability to regulate the expression
of a disproportionately large number of hepatic genes that include fatty acid, cholesterol
and glucose metabolism, urea biosynthesis, apolipoprotein synthesis, liver development,
and other transcription factors (e.g. HNF1 a and HNF6) [149-152]. Previous studies in our
group have shown better maintenance HNF4a maintenance at both the mRNA and protein
143
level after 7 days in culture [10]. In this study it was demonstrated that the microreactor
maintains better HNF4a protein expression at even long timepoints (21 days) in culture.
Monolayer cultures transfected with adenovirus at early timepoints following
plating demonstrate significant transgene transduction (as confirmed via GFP expression).
FACS analysis from the previous chapter revealed that for the given Ad-eGFP-DCPD MOI
-90% of GFP-expressing cells also express the DCPD transgene. PRHs maintained for 2
weeks in monolayer culture prior to adenovirus exposure demonstrate decreased transgene
transduction evidenced by fewer GFP-positive cells. The decreased transduction could be
due to a loss of necessary factors for either Ad-specific uptake (e.g. Coxsackie and
Adenovirus Receptor) or hepatocyte-specific replication machinery. These cultures have
lost hepatocyte morphology and appear to clump together into nodes. The appearance of
fibroblast-like cells suggests the proliferation of another cell type in these cultures.
Cultures are seeded with a hepatocyte-enriched-fraction (-95%). It is possible that a
population of the non-parenchymal cell (NPC) percentage is proliferating in these cultures
which are not susceptible to adenovirus uptake. The ratios of the different cell types in
culture at early timepoints most likely differ from the ratios present at later timepoints.
These NPCs do not appear GFP-positive.
DCPD was also shown to protect microreactor PRH cultures at early time points.
As discussed in the previous chapter the mechanism likely involves NO production. The
Ad-mediated toxicity was less evident in microreactor cultures maintained 2 weeks prior to
Ad exposure. Down-regulation of factors necessary for adenovirus uptake (e.g. CAR
receptor) could account for the decreased cytotoxicity.
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Spheroidal cell aggregates were previously used to seed microreactor cultures. To
maintain a similar timecourse of Ad exposure between monolayer and microreactor culture
the adenovirus was added directly to the spinner flasks as the PRHs formed spheroids. The
majority of the spheroids appear viable and GFP-positive following 24h spinner flask
incubation. Tissue-like structures appear to be forming after 24h in the microreactor (a
total of 48h after Ad exposure) and GFP has increased as expected. Use of spheroids is
non-ideal for these studies. Adenovirus exposure in the spinner flasks likely resulted in
equal access to all the PRHs due to the constant mixing. In order to study PRHs
transfected with Ad at later timepoints the Ad would be added to the microreactor -14
days following seeding. Unlike spinner flask incubation, mass transport considerations in
the microreactor probably do not allow for equal access to PRHs throughout the tissue
structures in each channel. Single cell seeding allows Ad vectors to be added to the early
timepoint and late timepoint microreactors under similar conditions. GFP expression
suggests that there is a decrease in transduction when PRHs are transfected at later
timepoints. As suggested earlier this could be due to a loss of necessary factors for either
Ad-specific uptake (e.g. Coxsackie and Adenovirus Receptor) or hepatocyte-specific
replication machinery.
A quantitative real-time PCR assay was developed that incorporates 2 sets of
primers, one of which converges upon the gap region in the (-) strand of the DHBV rcDNA
genome. DHBV cccDNA does not contain this gap region so these primers will only
amplify a signal in the presence of cccDNA.
Monolayer cultures demonstrate approximately 75% decrease in total DHBV
genome copies when transfected with DCPD after 2 weeks in culture. The majority of this
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DNA is in cccDNA form. Such a decrease correlates with the decrease of necessary
factors such as GD and HNF4. In contrast, DCPD-transfected microreactor cultures
demonstrate -300% increase in total DHBV genome copies when transfected with DCPD
after 2 weeks in culture. The well-to-well variability observed in microreactor culture
could have over-estimated the actual cell number present which would have led to a cells
being exposed to a higher Ad MOI. These data represent one biological replicate (2
technical replicates) and must be repeated to confirm this phenomenon.
One will also note that the microreactor cultures demonstrate total DHBV genome
copies that are an order of magnitude higher than the monolayer cultures. This evidence
implies that more effective replication is taking place in the microreactor. This observation
could be skewed by proliferation of different cell types in monolayer and microreactor
culture. Cell number was determined using GAPDH detection which is present in PRHs as
well as NPCs.
Currently, there is a need for an in vitro model that mimics a more natural HBV
infection process. This process begins with the viral particle binding to its host cell
receptor(s) and is followed by internalization, uncoating, nuclear delivery, and genome
repair. Previous work has demonstrated that later viral life cycle events are not rigidly
host-restricted [175]. In this study we have attempted to demonstrate that by providing
PRHs with the known DHBV internalization receptor that a 3D perfused culture could
facilitate the study of some of the early viral life cycle events. This work could be
extended to study HBV and potential human hepatocyte HBV receptors.
Ultimately, the goal is to learn more about human HBV and the in vitro system
characterized in this thesis can be extended towards this purpose. There are various
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putative receptors for HBV. This system could be extended to artificially deliver one of
the putative HBV receptors to primary rat hepatocytes. Due to the strict host-specificity of
these viruses this system represents a promising method to preferentially isolate putative
HBV receptors in cells with a well-differentiated liver phenotype. Successful HBV
replication would provide strong evidence for the involvement of the receptor in the HBV
life cycle.
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Chapter 5.
Conclusions and Recommendations
Chronic hepatitis B infection leads to a host of diseases that include cirrhosis and
hepatocellular carcinoma. Currently available therapeutics demonstrate modest efficacy
and/or promotion of resistant DHBV strains. These therapeutics are the products of
research based on the current understanding of the molecular biology of HBV. Research is
hampered due to the lack of in vitro systems in which the entire viral life cycle can be
studied. More is known about the later events in the viral life cycle (i.e. transcription,
encapsidation reverse transcription, virion assembly, export) due to studies in which the
viral genome is transfected into established hepatoma cell lines (e.g. HepG2, Huh7).
However, there is less understanding of the early stages that include virus attachment,
internalization, uncoating, genome repair, and nuclear transport. These cell lines do not
mimic natural infection which limits their usefulness. An in vitro system that will allow us
to target other aspects of the viral life cycle is needed for the development of future
therapeutics.
This thesis focused on developing an in vitro model of the early aspects of the
DHBV life cycle using a microfabricated reactor system that mimics key facets of the in
vivo liver microenvironment. Similar genome organization, virus structure, and replication
characteristics among hepadnaviruses warrant the study of hepadnaviruses found in other
species. Many of the principles of hepadnavirus life cycle were elucidated by studying
duck hepatitis B virus (DHBV) as a model for HBV. These principles include the
replication by reverse transcriptase [125], cccDNA formation [126], and host-range
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determinants [127-129]. DHBV was employed in this thesis as a surrogate model for
HBV.
Using length scales which foster cellular reorganization the microreactor was
designed to maintain cells in tissue-like units that are uniformly perfused with culture
medium. Previous characterization was done using a broad spectrum of gene expression,
protein expression, and biochemical assays [9, 10]. These metrics indicate that the
microreactor is capable of maintaining PRHs with a phenotype closer to that of native liver
than PRHs kept in conventional in vitro culture systems.
Recombinant adenovirus vectors were used to transfect primary rat hepatocytes
with DCPD in order to study the ability of a normally non-susceptible species to support
DHBV replication. Earlier studies have shown that primary rat hepatocytes are capable of
supporting DHBV replication upon adenoviral transfection of the viral genome, confirming
that the later events of the viral life cycle are not rigidly host-restricted [175]. We
generated recombinant vectors in which both DCPD and green fluorescent protein (GFP)
are incorporated in the adenoviral genome. DHBV replication was initiated in primary rat
hepatocytes when DCPD was transduced via adenoviral delivery, providing the first
evidence that DCPD is sufficient to cross the species barrier and establish a DHBV
infection in primary rat hepatocytes. Viral markers indicate a relatively inefficient process
in monolayer cultures but similar inefficiency is seen during DHBV infection of in vitro
cultures of PDHs. DCPD-transfected microreactor cultures demonstrate increased levels
of DHBV replication at longer timepoints. It should be noted that all these studies were
done in the absence of DMSO or hydrocortisone, known inducers of cellular
differentiation, which are standard additives that are almost universally applied to primary
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duck hepatocyte cultures. This culture system allows one to study isolated aspects of the
viral life cycle without such additives that are not present during natural infection.
Ultimately, the goal is to learn more about human HBV and the in vitro system
characterized in this thesis can be extended towards this purpose. There are various
putative receptors for HBV. Using this system it is possible to artificially deliver one of
the putative HBV receptors to primary rat hepatocytes. Due to the strict host-specificity of
these viruses this system represents a promising method to preferentially isolate putative
HBV receptors in cells with a well-differentiated liver phenotype. Successful HBV
replication would provide strong evidence for the involvement of the receptor in the HBV
life cycle.
Characterization of the multiple DCPD forms that appear in these DCPD-
transfected cultures would help to illuminate the trafficking of this receptor in these cells.
Unlike other studies that found only transient expression of DCPD at the cell surface these
studies demonstrate that the majority of the transfected receptor is expressed at the cell
surface. Further studies should be done to determine how the two proteins detected by the
DCPD antibody differ. Measurement of DCPD in supernatant samples would also help
clarify whether soluble DCPD is being produced via the DCPD transgene.
Further efforts to characterize the ratio of cell types present at both early and late
timepoints in microreactor culture is warranted. Current studies use GAPDH DNA which
is present in all cells. The differential proliferation of the various cell types present could
alter the actual DCPD-expressing cell population and therefore, alter the ratio of DHBV
copies per cell.
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This thesis also provided evidence that recombinant adenoviral vectors (with no
transgene or only eGFP trasngene) can mediate an alternative mechanism by which DHBV
can non-specifically penetrate primary rat hepatocytes. Initially it was assumed that given
the appropriate MOI the recombinant replication-incompetent adenovirus would be a
biologically inert device to effectively deliver the DCPD transgene. On the contrary, these
studies demonstrate that the adenoviral vectors have significant effects on these primary rat
hepatocytes. Measurement of adenoviral gene products would help to elucidate how the
adenovirus allows the subsequently added DHBV to artificially penetrate the primary rat
hepatocytes in the absence of DCPD.
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Appendix 1
MilliF Microreactor Assembly Protocol
Preparation prior to Day of Assembly.
NB: Never autoclave the polycarbonate reactor body parts.
NB: It is not necessary to autoclave the black cover plate or clamps.
For each bioreactor, the following reactor parts should be autoclaved prior to assembly:
Autoclave bag 1:
1) Four port connectors.
2) Five screws (4mm).
3) One retaining ring with o-ring attached.
Autoclave bag 2:
4) One custom cut Durapore filter (5gm pore size).
5) One thick gasket.
6) One thin gasket (pre-clean by rubbing with EtOH (70%) on a Kim-wipe)
Autoclave bag 3:
7) Two silicon scaffolds.
NB: Pick up using PLASTIC forceps to avoid scratching the silicon.
Autoclave bag 4:
8) Two blue autoclave sheets.
Autoclave bags 5, 6, 7, 8, 9 and 10:
9) Screwdriver.
10) Hexagonal connector driver.
11) Two syringe pistons.
12) Metal tweezers.
13) Plastic tweezers.
14) Metal flat-end tweezers.
Autoclave bag 11:
One polypropylene reservoir with custom cut tubing pieces attached (Figure 1).
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Figure 1: Tubing Lengths (for 2-pump experiments).
Axial Inlet Tubing:
Straight
15cm
Straight
15cm
Male luer lock w/hose barb +
Female luer
13cm
Silastic Lab Tubing-
0.062" ID
Cross-flow Inlet Tubing:
Male luer lock w/hose barb +
Female luer
Straight
15cm
Straight
15cm 13cm
Outlet Tubing:
Male luer lock w/hose barb +
Female luer
I
15cm
Silastic Lab Tubing-
0.062" ID
Extra Port:
Male luer lock plug +
Female luer
I
Silastic Lab Tubing-
0.062" ID
Reservoir Connector Tubing:
40mm
37mm
37mm
Attached to the 2 extra ports on the reservoir
A Attached to axial inlet port inside reservoir Silastic
Tubing-
Attached to crossflow inlet port inside reservoir 0.062" ID
Attached to axial outlet port inside reservoir
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15mm
~l·mv~vvu lu
---- ~c -~-- -I
I
40mm Attached to large port outside reservoir (the air filter is
hk el h1 +k i1; A IAA9 1 ID
catta e to t e reservo r us ng t s tu ng; .
Silastic 
Lab Tubing)
Female luer Male luer w/hose barb Male lock plug Straight connector
Preparation on Day of Assembly.
1) Incubate polycarbonate reactor body parts in 70% EtOH (30min) in a petri-dish.
2) Incubate black cover plate and clamps in 70% EtOH (30min).
3) Incubate Durapore filter in 10ml 1% BSA (in PBS) solution in a small petri-dish
(30min).
4) Incubate one silicon scaffold in 25ml collagen solution in a petri-dish (30min).
NB: Remove air bubbles from within the scaffold by shaking the petri-dish.
Assembly.
1) Place autoclaved blue sheets on the working surface inside a tissue-culture hood.
2) Transfer polycarbonate reactor body parts into a petri-dish containing 25ml PBS.
NB: Ensure the reactor body parts are completely immersed in PBS and that ethanol is rinsed out
of the parts. The significant surface tension between PBS and ethanol means that the reactor parts
move around on a film of ethanol when initially placed in PBS. If the reactor is well rinsed and
forcefully immersed into PBS, it will sink to the bottom.
3) Place polycarbonate reactor parts on the blue paper, using the plastic tweezers.
4) Remove excess PBS from the reactor parts using a vacuum manifold and pipette.
NB: Hold the pipette horizontal to the reactor to prevent scratching of the optical window.
NB: Leave some PBS in the reactor trough to provide the surface tension necessary to hold the
gasket in place.
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5) Place thin gasket into the reactor trough, using plastic tweezers.
6) Push thin gasket into the trough, using the rubber portion of the syringe piston.
7) Rinse collagen-coated silicon scaffold in PBS.
NB: This helps to minimize the attachment of cells to the top of the silicon chip.
8) Place collagen-coated silicon chip into the trough, using metal flat-head tweezers.
9) Push silicon chip into the trough, using the rubber portion of the syringe piston.
10) Place filter into the trough, using metal flat-head tweezers.
11) Push filter into the trough, using the rubber portion of the syringe piston.
NB: Ensure there are no bubbles remaining between the filter and scaffold.
12) Place non-collagen coated silicon chip into the trough, using metal flat-head tweezers.
13) Push silicon chip into the trough, using the rubber portion of the syringe piston.
14) Place thick gasket into the trough, using plastic tweezers.
15) Push thick gasket into the trough, using the rubber portion of the syringe piston.
16) Place retaining ring with O-ring attached into the trough, using plastic tweezers.
17) Push retaining ring into the trough, using the rubber portion of the syringe piston.
NB: With repeated use, the O-ring wears down => Replace after each experiment.
18) Add PBS (1-2 drops, using a iml syringe) to the reactor trough.
NB: This maintains the surface tension, required tohold the filter to the chip.
19) Place the bottom polycarbonate reactor part on top of the trough.
NB: It is reasonable to use gloved hands at this point.
20) Use three 4mm screws to attach the bottom and top polycarbonate reactor bodies.
NB: Tighten screws evenly to ensure an even distribution of stress on the O-ring.
21) Turn the reactor upside down so the optical window faces upwards.
22) Use two 4mm screws to attach the black cover plate to the reactor.
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NB: Make sure that the holes in the reactor line up with the holes in the black cover plate so that
the reactor is flush against the edge of the black cover plate.
23) Screw the 4 connectors into their respective ports, using the hexagonal driver.
24) Add HGM (15ml) to the reservoir.
25) Attach a 0.2gm filter to the gas exchange tubing on top of the reservoir.
26) Connect exterior tubing to the reactor and reservoir as shown (Figure 2).
NB: The reservoir interior has 2 x 37mm pieces of tubing attached to the inlet port and cross-flow
port and 1 x 15mm piece of tubing attached to the outlet port. There is also a 40mm piece of
tubing attached to the extra ports as shown in Figure 2. There is also a 0.104" piece of tubing
attached to the large port on the outside of the reservoir.
27) Prime reactor and tubing by running the system at the desired flow rates (lhr).
Axial Pump Setting (Top): (0.5ml/min) reactor • reservoir
Cross-flow Pump Setting (Bottom): (40pl/min) reactor • reservoir
28) Remove any air bubbles by flicking the lines with fingers.
NB: Keep reservoir elevated relative to the reactor; bubbles move upwards to the reservoir.
Precautions.
* Never touch the silicon scaffold, filter, retaining ring or gaskets with fingers.
* Clean the reactor tools with ethanol after each use.
* If the reactor leaks during priming, the O-ring probably needs replacing. Place the reactor back into
the sterile hood, disassemble and change the O-ring.
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Fieure 2: Tubine Attachments.
NB: After adding cells to the bioreactor, turn on the cross-flow pump first for a few seconds before
turning on the axial pump. This should ensure that the cells are pulled down into the channel.
Reservoir
Axial pump Crossflow pump
(Thick tubing) (Thin tubing)
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Appendix 2
MilliF Bioreactor Seeding & Maintenance Protocol
The system should have been primed for at least one hour prior to seeding.
Top View of MilliF:
-- 4-.
.- --- 4.
Day 1.
1) Remove any bubbles from the axial inlet and crossflow line by flicking the line with
fingers.
2) Clamp off the crossflow line; allow any bubbles to exit.
3) Remove crossflow tubing from the pump.
4) Disconnect female luer from the male luer lock w/ barbed hose on the outlet line.
5) Attach iml syringe to the short outlet tubing of the outlet line.
6) Turn on axial pump to fill the syringe.
NB: Keep unconnected tubes on the sterile autoclave paper.
7) Draw up lml of spheroids (100-300gm diameter) in another Iml syringe.
NB: Remove any bubbles in the syringe by inverting and gently tapping it.
8) Disconnect female luer from the male luer lock w/ barbed hose on the inlet line.
9) Pinch the short tubing on the inlet line and attach the syringe containing spheroids.
NB: Ensure that there is a liquid-liquid contact between the female luer and the syringe.
10) Hold spheroid syringe vertical and remove clamp on the crossflow line.
11) Hold both syringes vertical and slowly inject the spheroids into the reactor.
NB: Rotate the syringe to maintain the spheroids in suspension.
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12) When the piston on the syringe attached to the outlet line begins to move, the receptor
channels are full. If the piston does not move, repeat steps 7-11.
13) Re-clamp crossflow line.
14) Remove bubbles from axial inlet line using the syringe attached to the outlet line.
15) Remove syringe attached to the inlet line and reattach connectors.
NB: Ensure that there is a liquid-liquid contact between the connectors.
16) Remove syringe attached to the outlet line and reattach connectors.
NB: Ensure that there is a liquid-liquid contact between the connectors.
17) Unclamp crossflow line.
18) Turn on axial pump at 0.5ml/min.
19) Turn on crossflow pump in the forward direction (Rxr - Res) at 40-80gl/min.
20) Incubate bioreactors (370C, 8.5% CO2).
Day 2 (24 hours post-seeding).
1) Turn off axial flow pump and crossflow pump.
2) Clamp axial inlet and outlet tubing.
3) Unhook male luer/female luer on the crossflow inlet line.
4) Add a new 0.8/0.2tm filter between the male and female luer.
5) Reverse crossflow (Res - Rxr) and prime new filter using a high flow rate.
6) Turn off crossflow pump.
7) Re-hook male luer/filter/female luer to the crossflow inlet tubing.
8) Take off male lock plug on the extra port.
9) Turn on crossflow pump using a low flow rate; allow bubbles in reactor to escape.
10) Turn off crossflow pump.
11) Re-attach male lock plug to the extra port.
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12) Unclamp axial inlet tubing and outlet tubing.
13) Turn on axial pump and crossflow pump (still running in the reverse direction).
14) Replace media after 1 hour since some nutrients will be stuck on the new filter.
NB: Check for bubbles twice a day; Change in-line filter once every three days.
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Appendix 3
Giant Microreactor Assembly, Seesding, & Maintenance Protocol
Materials List:
* 1 Top window
* 1 Middle body
* 1 Bottom piece
* 6 small screws
* 6 large screws
* 2 port screws w/ O-rings
* 1 Middle-sized silicon O-ring
* 1 Large-sized silicon O-ring
* 4 screw end-barbed end connectors w/ silicon O-ring on screw end
* 2 oblong silicon gaskets w/ pin holes
* 2 polycarbonate scaffolds w/ pin holes
* 1 Oblong Millipore filter w/ pin holes
* 1 Metal retaining ring (oblong shape)
* 6 barbed end-barbed end connectors
* 6 female luer-barbed end connectors
* 2 female luer-sealed end connector
* 4 male luer-barbed end connectors
* 2 0.093" ID silicon peristaltic tubes (paralyne coated)
* 5 6" silastic tubes (Teflon tubing, 3/8" ID)
* 6 3" silastic tubes (Teflon tubing, 3/8" ID)
* 2 4" silastic tube (Teflon tubing, 3/8" ID)
* 2 reservoirs w/ two inner silastic tubes, two outer openings sealed with tubes, 1
outer tube for air filter
* 1 5 um inline filter
* 1 1.2 um inline filter
* 1 0.8/0.2 um inline filter
* 2 0.2 um inline filter
* 3 150 X 75 Pyrex dish
* 1 complete peristaltic pump (w/ 2 instech pumps)
* 2 13.5/35 VDC power supply (CAUTION: ALWAYS SET AT 13.5 VDC)
* Autoclaved blue paper (at least 3 squares)
* Tools: screwdrivers, tweezers, flat-head tongs, hex wrench
* 30 ug/mL type I rat tail collagen in 1X PBS
* 1% w/v BSA in 1X PBS
* 1X PBS
Assembly protocol
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1. Autoclave screws, connectors (place lewer connectors, except 1 male lewer and 1
sealed end, in separate bag), reservoir, silastic tubing (Teflon tubing), O-rings, tools
(except screwdrivers), gaskets, Millipore filter, retaining ring, 2 Pyrex dishes and
blue paper.
2. Scrub polycarbonate Giant RXR body parts w/ alconox, rinse with milliQ water,
place parts in previously autoclaved Pyrex dish, cover parts with milliQ water.
3. Replace water with 70% EtOH and let stand at least ten minutes before putting in
hood. Make sure all RXR bodies are completely submerged. CAUTION:
POLYCARBONATE SHOULD NOT BE EXPOSED TO ETOH FOR MORE
THAN 30 MINS.
4. Place polycarbonate scaffolds in Petri dish, cover with alconox water, shake gently,
remove alconox, cover with milliQ water to rinse, shake gently, rinse repeatedly.
5. Place polycarbonate scaffolds w/ body parts in Pyrex dish w/ milliQ water, put in
sonicator for 2 mins.
6. Remove milliQ water, cover parts with 70% EtOH, sonicate for 2 mins. Leave parts
in EtOH. CAUTION: POLYCARBONATE SHOULD NOT BE EXPOSED TO
ETOH FOR MORE THAN 30 MINS.
7. Place body parts in Pyrex dish in sterile hood, along with: autoclaved Pyrex dish,
tools (including EtOH sprayed-down screwdrivers), connectors (except lewer
connectors, include 1 male lewer and 1 sealed end), screws, reservoir, tubing, 0-
rings, gaskets, Millipore filters, retaining ring, and blue paper. Spray all autoclave
packets thouroughly with EtOH before putting them in the hood and keep them
away from the blue paper surface that the reservoir is on.
8. Cover surface of working area in sterile cabinet with autoclaved blue paper.
9. Fill one autoclaved Pyrex dish ¾ full with IX PBS, this will be used to rinse all
parts. Fill a 10 cm Petri dish with IX PBS to rinse scaffolds separately from other
parts.
10. Fill the other autoclaved Pyrex dish ¾ full with 70% EtOH, and use the flat tongs
to place the two peristaltic tubings in the ethanol, swirling the tubes around the dish
to get the inner tubing surfaces exposed as well. Make sure all tube ends are
submerged in the ethanol.
11. Place collagen solution (at least 10-15 mL) in a 10 cm Petri dish. Do same for 1%
BSA solution.
12. Rinse both scaffolds in 1X PBS. Put the top scaffold into the collagen solution,
shaking gently until no air bubbles are seen. The corresponding bottom scaffold can
stay in the pBS or be put in another Petri dish with PBS if you are keeping track of
many RXRs. For polycarbonate scaffolds, keep in collagen solution for 2 hours,
and then dry for 2 hours by balancing the scaffold on a 60 mm dish inside a 10 cm
dish in side the hood. For silicon scaffolds only 30 min in the collagen solution is
required.
13. Rinse filter in PBS and then place in the BSA solution for at least 30 minutes.
14. Use tongs and tweezers to take out middle body part (sides may be touched by
gloved hands, but should be avoided) from EtOH, rinse in IX PBS, and place on
blue paper top-side up.
15. Using tweezers, rinse middle-sized silicon O-ring in IX PBS (this helps parts
interact with each other more smoothly), place O-ring in its channel in top of
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middle part. Use tweezers to hold down O-ring while flathead of tongs is used to
smoothly place the O-ring into channel to avoid tearing the O-ring.
16. Rinse top window in IX PBS, place on top of middle body part.
17. Use the 6 small screws to secure window on middle part (PBS rinsed). Tighten
screws (lightly at first) in a crisscross pattern, eventually tightening without
cracking polycarbonate parts (don't overly tighten). Make sure O-ring in
compressed uniformly.
18. Screw in port screws slowly and loosely to middle body part, make sure there are
no burrs on that screw threads catching that can damage the threading on the
reactor body
19. Tighten port screws, stop at a little resistance. Otherwise you can break the flow
channel inlet and outlet, compression of the O-ring is all that is needed to seal the
injection port.
20. Keep middle/top window assembly open chamber face down on the sterile blue
paper. Use the hex wrench to lightly-tighten 2 screw end-barbed end connectors to
middle body part.
21. Flip the RXR body around so that the open pocket is facing up. Be very careful not
to wave hands or arms over the reactor now.
22. Using tools, rinse 1 silicon gasket in PBS, place gasket in middle body part, using
pins/pin holes as a guide. Use flathead of tongs to lay gasket down flat and make
sure no air bubbles are stuck under the gasket.
23. Place dried top scaffold in middle body atop the gasket, use pin/pin holes as guide.
Make sure scaffold is flat on gasket and that the letter or number symbol is facing
you at the top pin to ensure alignment with the bottom support scaffold.
24. Place filter in middle body atop scaffold using pin/pin holes as guide. Flatten with
tongs onto scaffold. Be especially careful not to tear the filter, as this will affect
control over cross-flow.
25. Using tools, rinse support scaffold in PBS if not already in PBS, place scaffold in
middle body atop Millipore filter using pin/pin holes as guide. Make sure scaffold
is flat and that the letter or number is at the top pin and facing you to ensure the
best alignment.
26. Using tools, rinse second silicon gasket in PBS, place gasket in middle body atop
scaffold using pin/pin holes as guide. Flatten with tongs onto scaffold. The pins
should only extend about halfway up into the holes on this gasket.
27. Using tools, rinse retaining ring in PBS, place ring in middle body atop gasket with
channel for O-ring facing upward.
28. Using tweezers, rinse large-sized silicon O-ring in IX PBS, place O-ring in its
channel between retaining ring and middle part. Use tweezers to hold down O-ring
while flathead of tongs is used to smoothly place the O-ring into channel.
29. Rinse bottom piece of RXR in PBS. Place on middle body part, and use the large
screws to secure. As with the top window, tighten screws (lightly at first) in a
crisscross pattern, eventually tightening without cracking polycarbonate parts
(don't overly tighten). Make sure O-ring in compressed uniformly.
30. Use hex wrench to lightly-tighten 2 screw end-barbed end connectors to bottom
piece. Flip RXR top-side up with bottom connectors towards assembler.
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31. Place one 6" silastic tube (or Teflon tube) into right side connector and one into
bottom-right connector. Place one PBS rinsed 3" silastic tube (or Teflon tube) into
bottom-left connector and one into left side connector.
32. Put male luer-barbed end connector into each 3" silastic tube (Teflon tube) at the
bottom left port. Attach a female luer-barbed end connector onto connector coming
out of right side of top chamber. Attach a female lewer-sealed end connector onto
connector coming out of bottom right chamber. Note: It's easiest to add these
connectors onto the tubing before they are wrapped up in blue paper with the
reservoir and other tubing and autoclaved.
33. Attach a 4" silastic tube (Teflon tube) between connector coming out of the right
side of the top chamber and the reservoir (no inner silastic tube in reservoir).
34. Put complete peristaltic pump in safety cabinet connected to power supplies.
35. Rinse peristaltic tubes in PBS, evenly distribute a light coat of pump grease on tube
length between pump locks.
36. Turn pump on to a slow speed and guide peristaltic tube into each Instech pump.
Keep pump going on for a short period to allow all PBS to clear out.
37. Put 1 barb-barb end connector onto each end of each peristaltic tube. With the
Instech pumps facing assembler, connect one 6" silastic (Teflon) tube onto left end
of left peristaltic tube, connect this to reservoir (to an inner silastic tube in
reservoir).
38. Connect right end of left peristaltic tube to silastic (Teflon) tube out of left side
connector on RXR body.
39. Connect one 6" silastic (Teflon) tube onto left end of right peristaltic tube, connect
this to reservoir (to an inner silastic tube in reservoir). Connect right end of right
peristaltic tube to silastic (Teflon) tube out of bottom-left connector on RXR body.
40. Put 0.2 um inline filter in tube for air filter in reservoir. Fill reservoir with 30 mL of
HGM (w/ or w/o BSA, depending on necessities of experiment).
41. Turn on left Instech pump at 3 mL/min, counterclockwise (calibration should be
done before run). Allow top chamber of RXR to fill with HGM.
42. Turn on right Instech pump at lmL/min, counterclockwise. Flip RXR, bottom-side
up, put reactor at a 450 angle so that bottom chamber fills up from bottom up
(inflow tube on bottom). If bottom chamber starts to have a lot of air bubbles or
foam starts to develop, open locked lewer connector slightly to relieve pressure and
get rid of bubbles/foam. Once all foam/bubbles are cleared out, lock connector
again.
43. Let system prime for -I 1 hour.
Seeding protocol
All seeding is done inside sterile cabinets unless otherwise noted. Spheroids should be
filtered (50 pm and 300 [tm mesh), spun down at 50 g for 3 mins, resuspended in cold
fresh medium, and put on ice before beginning this protocol.
1. Turn off pumps and unscrew top window, remove it, and place it on sterile
autoclave paper.
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2. Turn on pumps, reverse flow on crossflow line so that flow is going from top
chamber to bottom chamber. Increase crossflow rate to 2.5 mL/min. Leave main
flow on at 3 mlimin.
3. Seed reactor by pipetting -~ 1mL of spheroid suspension evenly on seeding scaffold.
Pipette gently, making sure spheroids are evenly distributed. Spheroids may be
pipetted back up if doing so will not shear the spheroid.
4. Turn off main flow and rock reactor body back and forth to get even seeding of
scaffold. Observe channels as well as possible. If all channels are not seeded
properly, a smaller volume of spheroid suspension may be added to the required
area of the scaffold. Make sure top chamber liquid level is always above scaffold
by turning on main flow if it is too low. This prevents cells from drying.
5. Turn off all flow. Replace top window and screw back on in a similar fashion as
done during assembly to ensure uniform compression of O-ring. Turn main flow on
at 3 mL/min, and crossflow at 2.5 mL/min. Put reactor in 370 C incubator.
6. Change medium 1-2 hours after seeding. Put in 30 mL of fresh medium in
reservoir.
Inserting Filters and Reversing Crossflow
This protocol should be followed such that crossflow is reversed 24 hrs after seeding.
Priming of filters requires an extra reservoir. However, all filters necessary can be primed
from the same pump assembly.
1. Soak one peristaltic tube in 70% EtOH for <15 mins. Rinse in IX PBS and place
around pump head by turning pump on to a low setting. Grease tube before placing
on head.
2. Insert one barbed end-barbed end connector to each end of peristaltic tube.
3. With pump heads facing user, attach one 6" peristaltic tube (Teflon tube) to left end
of peristaltic tube. Attach other end to reservoir (inner silastic tube).
4. Attach one 3" peristaltic tube (Teflon tube) to right end of peristaltic tube, insert
male lewer-barbed end connector into free end and attach a 5 [tm inline filter to this
connector. Attach a female lewer-barbed end connector to free end of filter. Repeat
this step for 1.2 [pm inline filter and 0.8/0.2 [im inline filter, placing a 3" silastic
tube (Teflon tube) between each filter.
5. Connect 0.8/0.2 tm inline filter to reservoir (inner silastic tube) with a 4" silastic
tube (Teflon tube). If more than one reactor requires inline filters, repeat step 4 for
those filters before attaching this final tube to the reservoir.
6. Place one 3" silastic tube to open connector on reservoir (no inner silastic tube),
insert a female lewer-barbed end connector into free end and seal with a male
lewer-sealed end connector. Insert 0.2 [pm inline filter into air intake tube.
7. Put 30 mL of fresh medium into reservoir. Turn on pump in a counterclockwise
direction at full speed.
8. Hold filters up such that they will be filled from the bottom up so that most air is
removed from the filter. After filters have been filled with medium, shake them and
tap them gently against pump or sterile cabinet to shake out any air bubbles that
may have been trapped inside them.
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9. Once all air bubbles are cleared, allow filters to prime for -1 hour.
10. Take reactor out of incubator and place in sterile cabinet. Turn off pumps.
11. Open lewer locked connectors in outflow line. Turn on main flow just so liquid
level gets to end of male lewer connector and then turn off.
12. Remove 5 CIm inline filter from lewer lock and lock with the outflow line of the
reactor assembly. Detach female lewer lock connector from 0.8/0.2 [tm inline filter
outlet and attach this filter to female lewer-barbed end connector left open on
reactor assembly.
13. Reverse crossflow on reactor so that it flows from bottom chamber to top chamber,
and set at 1 mL/min. Hold reactor at a 450 degree angle such that the inlet of the
bottom chamber is lower that the sealed end. Open the sealed end slightly to allow
air bubbles to escape through this opening. Once all air bubbles are removed, close
seal. Turn on main flow at 3 mL/min.
14. Change medium with 30 mL of fresh, 37oC-warmed medium. Medium maybe
changed every 24, 48 or 72 hours beyond this point depending on the needs of each
experiment. Inline filters should be changed every 72 hours by repeating this
protocol.
179
Appendix 4
Multi-well Microreacttor Assembly, Seeding, & Maintenance Protocol
(taken from "Multi-well Bioreactor Manual for use with Generation E Systems")
Chapter 1: Prior to Use
The following steps can all be done outside of the hood.
1.1 Cleaning and Washing Components
1. 1 1 Cleaning Fluidic and Pneumatic Plates
Components you will need:
* Fluidic Plate (1)
* Pneumatic Plate (1)
1. Place fluidic and pneumatic plates in a tub filled with a 1-3% 7x soap solution.
2. Wash plates thoroughly. Look for any debris blocking the small channels and holes in
both the fluidic and
pneumatic plates. In particular, pay attention to the angled channels in the fluidic plate.
Use compressed air to clean the debris. If compressed air cannot dislodge debris, ask for
assistance.
3. After washing, rinse plates in distilled
4. Dry off all components thoroughly.
t.1.2 Ceaning Reactor Well Components
Components you will need:
* Scaffolds (12)
* Gaskets (12)
* Retaining Rings (24)
* Filter Supports (12)
NOTE: Experience shows that it helps to prepare 1 to 2 extra of each component before
experiment.
Tools you will need:
* Glass Dish (1)
* Petri Dish (1)
Prior to use of the reactor, these components must be cleaned as follows:
1. Place scaffolds in Petri dish filled with a 1-3% 7X soap solution. Place retaining rings,
filter supports,
gaskets in a glass dish filled with an 1-3% 7X soap solution.
2. Sonicate these components for 10 to 15 minutes.
3. After sonicating, rinse all components in XX water until soap is rinsed off.
4. Fill dishes with XX water and sonicate these components for 10 to 15 minutes.
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5. Fill dishes with 70% ethanol and sonicate all components except fluidic and pneumatic
plates for 5 to 10
minutes.
6. Dry off all components.
Components you will need:
* Fluidic Plate (1)
* Scaffolds (12)
* 24 Pack - Filters (1)
* 12 Pack - Filters (1)
* Gaskets (12)
* Retaining Rings (24)
* Filter Supports (12)
Tools you will need:
* Tweezers (1)
* Tamping Tool (1)
Autoclave Instructions
1. Place all the remaining tools into one autoclave bag and seal.
2. Place each set of components into a separate autoclave bag and seal.
3. All components except the membrane should be put in a standard autoclave on a dry
cycle with 45
minutes of sterilization and 15 minutes of drying.
DO NOT AUTOCLAVE PNEUMATIC PLATE! The pneumatic plate does not need to be
autoclaved, and the material
will melt if placed in autoclave.
Make sure that you have been officially trained to use EtO Chamber.
Components you will need:
* Polyurethane Membrane (wrapped in blue paper) (1)
Tools you will need:
* EtO Chamber
EtO Chamber Instructions
1. Label the autoclave bag for each membrane with the date of sterilization.
2. The membrane should be sterilized in an EtO autoclave and outgassed for a minimum of
3 days.
NOTE: To be efficient, you can sterilize more than one membrane at a time.
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Components you will need:
* Pneumatic Plate (1)
Tools you will need:
* Tape (1)
* X-Acto Knife (1)
Preparing Pneumatic Plate
1. Spray pneumatic plate 70% ethanol and dry very well. (The device will not work well if
there is any liquid
in the pneumatic channels.)
2. Wipe the bottom of the plate with 100% isopropanol and let dry.
3. Cover the bottom of the plate with tape making sure all channels are covered and there
are no air bubbles
in the tape.
4. Press tape firmly to plate to ensure adhesion along channels.
5. Carefully cut holes for screws with X-Acto knife. Make sure to not peel up tape near
pneumatic channels,
and be sure to fully remove tape that has been cut away.
Chapter 2: Prior to Start of Experiment
The following steps should all be done in sterile environment.
2.1 Coating scaffolds with collagen
Components you will need:
* Scaffolds (12)
Tools you will need:
* Petri Dish (2)
Solutions you will need:
* 10 mL Collagen Solution of Type 1 rat tail collagen (30 ptg / mL)
* PBS
* 70% ethanol
To coat the scaffolds with collagen:
If you are using SILICON scaffolds:
1. Fill petri dish with 70% ethanol.
2. Place scaffolds in ethanol solution to remove all air bubbles.
3. To remove air bubbles, check under microscope or wash with PBS.
4. Fill 2nd petri dish with collagen solution.
5. Soak the scaffolds in the collagen solution for 30 to 45 minutes. Pipette the collagen
solution onto the scaffolds.
6. Rinse scaffolds in dish with PBS to remove excess collagen.
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If you are using POLYMER scaffolds:
1. Fill petri dish with 70% ethanol.
2. Place scaffolds in ethanol solution to remove all air bubbles.
3. To remove air bubbles, check under microscope or wash with PBS.
4. Fill 2nd petri dish with collagen solution.
5. Soak the scaffolds in the collagen solution for 2 hours.
6. Dry the scaffolds by allowing them to stand along the edge of the Petri dish. Excess
collagen will drop to the base of the scaffold.
7. Aspirate off excess collagen.
8. Rinse scaffolds in dish with PBS prior to placing them into reactor.
22 Prepiar ng otheri compon-ents
Components you will need:
* 24 Pack Filters (1)
Tools you will need:
* Petri Dish (1)
Solutions you will need:
* PBS with 1% BSA(Sterile)
Component Preparation:
1. Fill petri dish with PBS with 1%
minutes.
BSA and soak filters in this solution for at least 30
Chapter 3: Reactor Assembly
The following steps should be done under the hood.
Components you will need:
* Lid (A 96 Well Plate Lid works fine) (1)
* Polyurethane Membrane (1)
* Fluidic Plate (1)
* Pneumatic Plate (1)
* Hex Screws (14)
Tools
*
you will need:
Hexdriver (1)
Sterile Blue Paper (2)
Reactor Assembly:
1. Spread out 2 sheets of blue paper in the hood to provide a sterile surface.
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2. Spray base of pneumatic plate with ethanol being careful not to get it in the fluidic
channels. Do not spray top of pneumatic plate with any fluid because fluid in channels will
prevent pumping. Dry pneumatic plate.
3. Place polyurethane membrane on top of the pneumatic plate using the alignment pins as
guides. Center the holes in the membrane around the screw holes. Make sure to eliminate
folds that would prevent the membrane from laying flat between the plates. When handling
the membrane, try to only touch the corners and keep the membrane as sterile as possible.
4. Place fluidic plate over the pneumatic plate and membrane.
5. Flip the assembly over and make sure that the membrane covers all the fluidic channels.
6. Tighten screws starting from the middle and working outward. Do not tighten all the
way first. Screw in all screws, and then go back and tighten until the membrane becomes
clear between the fluidic and pneumatic plates. This is a sign that you have a good seal.
7. Once you have a good seal, cover the fluidic plate with the lid; you are ready to prime
the reactor.
Chapter 4: Priming the Reactor
The following steps should be done under the hood.
Components you will need:
* Reactor Assembly (1)
* Reactor Controller (1)
Solutions you will need:
* 50 mL warm HGM
Priming the Reactor:
1. Fill each reservoir well with roughly 1.5 mL of HGM.
2. Connect the pump controller to the vacuum and pressure sources. Both gauges should
read 30 -+ 5 kPa when flowing.
3. Connect the tubing from the controller to the reactor assembly.
4. Turn on the controller to UPWARD setting.
5. Begin flowing in the UPWARD setting.
6. Look to see if fluid is pumping into the reactor well.
7. Once you have verified that your system is functioning, fill reactor wells and make sure
fluid connects across the surface channel.
YOU SHOULD SET UP YOUR REACTOR THE DAY BEFORE AND ALLOW TO
RUN OVERNIGHT IN INCUBATOR AND REFRESH MEDIA BEFORE SEEDING
CELLS.
Chapter 5: Setting up the Wells
The following steps should be done under the hood.
Components you will need:
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* Assembled Reactor (1)
* 24 Pack Filters (1)
* Gaskets (12)
* Filter Supports (12)
Tools you will need:
* Glass Dish (1)
* Tweezers (1)
* Tamping Tool (1)
Solutions you will need:
* PBS
Setting Up Reactor Wells:
1. Place all filter supports in 50 mL Falcon Tube.
2. Fill Falcon Tube with PBS and tap the bottom of the tube to remove trapped bubbles
from filter supports.
3. Place all gaskets in dish of PBS.
4. Place gaskets in all of the reactor wells. Push down with tamping tool.
5. Pour filter supports into glass dish or 90 mm petri dish.
6. Place filter support in all reactor wells with concentric rings facing up.
7. Push down with tamping tool.
8. Rinse filter gently in PBS and then place one filter in all wells.
9. Rinse scaffolds gently, and gently place one in each reactor well.
10. Put one retaining ring in each well. Push them down gently as too much pressure can
cause the silicon scaffolds to break. However, still make sure that the ring is tight and
pushed down all the way to ensure the path of the fluid is through the filter and scaffold
and not around it.
Chapter 6: Seeding Cells
Components you will need:
* Reactor Assembly (1)
* Reactor Controller (1)
Tools you will need:
* P1000 Pipette + Wide Orifice Tips
Solutions you will need:
* HGM
* Isolate Cell Suspension
1. If your reactor has been priming overnight, aspirate as much media as possible from
both the reactor and reservoir making sure to leave a thin layer of media above the scaffold
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in the reactor well and the filter in the reservoir well as to not introduce air bubbles beneath
the filter.
2. Add back cold, fresh medium to the reactor well only. Do not create a fluidic connection
between the reactor well and reservoir well.
6 .2 Seeding the Singie Cells
1. Make sure that the reactor is set for downward flow through the scaffold.
2. Check to make sure the retaining rings are pushed all the way down.
For 800 channel scaffolds:
3. Use a P1000 pipette.
4. Pause flow.
5. Ensure that the reactor well and reservoir well are not fluidicially connected.
6. Hold pipette straight up and slowly pipette the desired amount of your cell suspension in
a pattern over the entire scaffold.
7. Check seeding under microscope. See appendix for tips if poorly distributed.
8. Once you are comfortable with seeding distribution, resume downward flow and
immediately begin fill reservoir to fill line with media (approximately 2.5 mL - 2.7 mL).
Make sure that you have no dry spots
across the fluidic channel as this will disrupt oxygen transport.
6.3 Setting the Fiowrate and Reversal Time
1. Set the controller for reverse flow and select a flowrate.
2. Set a reversal time of 8 hours.
Chapter 7: Experiment Maintenance
7.1 4 Hours After Experiment Start
The following steps can be done outside of the hood except where noted.
Components you will need:
* Reactor Assembly (1)
* Reactor Controller (1)
Tools you will need:
* 10 ml pipette
* Aspirator
Solutions you will need:
* 50 mL HGM - Warm
1. Remove your reactor from the incubator and walk with it carefully to the hood trying not
to shake the reactor as media may spill out of the channel.
2. Under the hood, remove the lid from your reactor and aspirate off any media from the
lid and on the surface of the reactor plate.
186
3. Aspirate media from the reservoir wells by taking your aspirator tip and bringing it to
the top of the retaining ring and aspirating off the media. Be careful to not aspirate off
media to the point of creating air bubbles under the filter as this interrupts the flow through
the reactor.
4. Aspirate media from reactor wells by taking your aspirator tip near the wall of the
reactor well. Be sure not to aspirate media directly from above the cells. Be sure to leave
approximately 1 - 2 mm of media above the cells as to not disrupt them significantly.
5. Add 2.5 - 2.7 mL to each reservoir well filling only to the fill line. Be careful and keep
your pipette clear of bubbles. Make sure that you have no dry spots across the fluidic
channel as this will disrupt oxygen transport.
6. Cover your reactor and return your reactor to the incubator.
7. Make sure the pressure and vacuum gauges are bouncing between 30 + 5.
7.2 24 Hours After Experiment Start
The following steps can be done outside of the hood except where noted.
Components you will need:
* Reactor Assembly (1)
* Reactor Controller (1)
* 12 Pack Filters (1)
Tools you will need:
* 10 ml pipette
* Aspirator
* Tweezers (1)
* Tamping Tool (1)
* Petri Dish (2)
Solutions you will need:
* 50 mL HGM - Warm
* 1% BSA Solution
* PBS
1. Begin soaking 12 new filters in petri dish filled with 1% BSA Solution.
2. Remove your reactor from the incubator and walk with it carefully to the hood trying not
to shake the reactor as media may spill out of the channel.
3. Under the hood, remove the lid from your reactor and aspirate off any media from the
lid and on the surface of the reactor plate.
4. Aspirate media from the reservoirs by taking your aspirator tip and bringing it to the top
of the retaining ring and aspirating off the media. Be careful to not aspirate off media to the
point of creating air bubbles under the filter as this interrupts the flow through the reactor.
5. Aspirate media from reactor wells by taking your aspirator tip near the wall of the
reactor well. Be sure not to aspirate media directly from above the cells. Be sure to leave
approximately 1 - 2 mm of media above the cells as to not disrupt them significantly.
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6. Remove retaining ring from reservoir side, and place aside in petri dish filled with PBS.
7. Remove filters from reservoir and discard.
8. Gently place new BSA-soaked filters in reservoir. Tamp in place.
9. Put one retaining ring in each well, and push down firmly with tamping tool to ensure
tight fluidic seal.
10. Put -2mL of new warm media in each reservoir well being careful to keep your pipette
clear of bubbles.
Make sure that you have no dry spots across the fluidic channel as this will disrupt oxygen
transport.
11. Cover your reactor and return your reactor to the incubator.
12. Make sure the pressure and vacuum gauges are bouncing between 30 ± 5.
7.3 More than 24 Hours After Experiment Start
1. Remove your reactor from the incubator and walk with it carefully to the hood trying not
to shake the reactor as media may spill out of the channel.
2. Under the hood, remove the lid from your reactor and aspirate off any media from the
lid and on the surface of the reactor plate.
3. Aspirate media from the reservoirs by taking your aspirator tip and bringing it to the top
of the retaining ring and aspirating off the media. Be careful to not aspirate off media to the
point of creating air bubbles under the filter as this interrupts the flow through the reactor.
4. Aspirate media from reactor wells by taking your aspirator tip near the wall of the
reactor well. Be sure not to aspirate media directly from above the cells. Be sure to leave
approximately 1 - 2 mm of media above the cells as to not disrupt them significantly.
5. Put -2mL of new warm media in each reservoir well being careful to keep your pipette
clear of bubbles.
Make sure that you have no dry spots across the fluidic channel as this will disrupt oxygen
transport.
6. Cover your reactor and return your reactor to the incubator.
7. Make sure the pressure and vacuum gauges are bouncing between 30 + 5.
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